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The inhibitory glycine receptor is a target for both alcohols and volatile 
anesthetics.  The function of strychnine-sensitive glycine receptors is enhanced in the 
presence of clinically relevant concentrations of ethanol and longer chain alcohols as well 
as volatile anesthetics.  Site-directed mutagenesis techniques have identified residues in 
transmembrane segment (TM) one (I229), two (S267) and three (A288) that mediate the 
effects of alcohols and anesthetics, and drug binding is hypothesized to involve all amino 
acids from all four transmembrane segments.  Here, by the use of crosslinking studies in 
receptors expressed in Xenopus laevis oocytes, we determined that S267 and A288 are 
near-neighbors that face one another in three-dimensional space.  This provided an 
improved model of orientation for these two transmembrane segments and provides 
insight towards the location and role of the TM2-TM3 interface.  Second, changes in the 
accessibility to the binding cavity and changes in the volume of this binding cavity were 
examined during channel gating for amino acids in all four TMs using mutagenesis and 
 vii
sulfhydryl-specific reagents of different lengths. S267C was accessible to short chain 
(C3-C8) methanethiosulfonate (MTS) compounds in both open and closed states, but was 
only accessible to longer chain (C10-C16) MTS compounds in the open state.  Reaction 
with S267C was faster in the open state.  Mutated residues more intracellular than 
M263C in TM2 did not react, indicating a floor of the cavity.  I229C and A288C showed 
state-dependent reaction with MTS only in the presence of agonist.  Reaction of propyl 
MTS with A288C receptors abolished the effect of the anesthetic isoflurane, providing 
strong support that A288C is contributing to a binding site for alcohols and anesthetics. 
Four of twelve mutants tested in TM4 (W407C, I409C, Y410C and K411C) reacted with 
propyl MTS, providing information on which amino acids were in water-accessible 
positions and thus possible candidates for involvement in alcohol and anesthetic binding.  
These data demonstrate that the conformational changes accompanying channel gating 
increase accessibility to amino acids critical for drug action, which may provide a 
mechanism by which alcohols and anesthetics can act on glycine (and likely other) 
receptors. 
 viii
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Amino acids positions are named using their standard single letter amino acid code and 
the numerical position of the amino acids in the primary amino acid sequence.  For 
example a serine at position 267 is abbreviated S267. 
 
Mutant amino acids positions are named by their standard single letter amino acid code 
from the wild type and numerical position of the amino acid in the primary protein 
sequence, followed by the one letter amino acid code of the introduced, mutant amino 




1.1 Alcohols and Anesthetics 
Alcohol has been used for at least 7000 years.  The earliest known wine was 
discovered in archaeological excavations of a Neolithic village in present day Iran 
(McGovern et al., 1996).  Examples of alcohol use abound in history from the Romans, 
who celebrated Dionysus, the god of wine, to social drinkers of the present day. 
Ethanol can be described as an “organic derivative of water” where with a single 
ethyl group replaces one of the hydrogen atoms of a water molecule (McMurry, 1996).  
This seemingly small change results in the physical and the behavioral properties of 
alcohol.  Alcohol is a central nervous system depressant, which means it depresses 
normal brain functions.  Some of the intoxicating effects of alcohol include relaxation, 
sedation, motor incoordination, and impairments of cognition and memory.  While many 
people enjoy pleasurable effects of alcohol, others abuse this drug.  Alcoholism is a 
disease defined by an individual’s need for alcohol and includes craving for and a 
physical dependence on this drug.  Understanding the molecular basis for this disease is 
key to effective treatment and prevention. 
It is difficult to imagine most modern day medical operations without general 
anesthesia.  Since 1846, when general anesthesia was first demonstrated, these drugs 
have been invaluable in operating rooms.  Anesthetics cause immobility, sedation, 
hypnosis, and amnesia, and often include further components, such as relaxation, 
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analgesia, and anxiety reduction (Rudolph and Antkowiak, 2004).  These drugs ensure 
that a patient does not move during surgery or remember the procedure.  Some volatile 
(inhaled) anesthetics, such as chloroform, were used clinically in the past, and others, 
such as isoflurane, are still used today.  Understanding how anesthetics act is important to 
areas of neuroscience involving consciousness, arousal, and perception.  Additionally, 
understanding how anesthetics work at a molecular level could help devise administration 
of safer anesthetics with fewer, and less dangerous, side effects.  Like alcohols, 
anesthetics are central nervous system depressants.  Overall, alcohols and anesthetics 
share many behavioral and pharmacological effects. 
Alcohols and volatile anesthetics are drugs that affect the brain, but the molecular 
mechanism by which these drugs cause their effects has been controversial.  Initially, 
alcohols and anesthetics were believed to disrupt the membranes surrounding cells in a 
nonspecific manner.  This view has changed in the past 20 years, as these drugs were 
shown to have direct effects on proteins in the brain.  Now, alcohols and anesthetics are 
known to have specific protein targets in the brain, including ion channels. 
 
1.2 Ligand-Gated Ion Channels 
Ion channels are transmembrane proteins, formed from one or more protein 
subunits.  Shaped like tunnels, they form pores through the plasma membrane with gates 
that open and close to allow ions to diffuse down their chemical gradient and move in or 
out of a cell.  Ions are unequally distributed, creating a separation of charge across a 
membrane, called an electrical potential.  When an ion channel is open, a million ions can 
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flow in or out of the cell per second, resulting in an electrical signal or current 
(Siegelbaum and Koester, 2000). 
There are two major classes of ion channels defined by the way the channel 
opens:  voltage-gated and ligand-gated.  Voltage-gated ion channels have sensors for the 
electrical potential across the membrane and open when the cell is at a specific membrane 
potential.  Ligand-gated ion channels (LGIC) open when a specific chemical signal, or 
neurotransmitter, is released from a neuron, diffuses through a gap known as a synapse, 
and binds to receptors on ion channels of a second neuron.  The binding of the 
neurotransmitter causes the gates of ion channels to open.  In this way, the ligand-gated 
ion channel family of receptors mediate fast communication in the nervous system, 
allowing for orchestration of our physical and mental activities (Lobo and Harris, 2004). 
Diseases called channelopathies occur when ion channels do not function 
properly. Some examples are epilepsy, cystic fibrosis, heart arrhythmia and high blood 
pressure.   Ion channels are also the target of many types of drugs and toxins, which can 
alter the fundamental communication between cells.  Of interest here are the changes 
caused by alcohols and anesthetics.  Multiple ligand-gated ion channels are affected by 
anesthetics and alcohols, including the glycine and γ-aminobutyric acid (GABA) 
receptors as well as glutamate, acetylcholine, and serotonin receptors. 
 The pentameric ligand-gated ion channels are believed to have a common 
evolutionary origin (Ortells and Lunt, 1995).  They have notable conservation in their 
sequence alignments (Le Novere and Changeux, 1999).  Included in this family of 
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channels are the inhibitory glycine, GABAA and GABAC receptors, and the excitatory 
nicotinic acetylcholine and serotonin 5-HT3 receptors. 
 
1.3 Glycine Receptors 
The two major inhibitory neurotransmitters in the central nervous system are 
glycine and GABA.  Both transmitters bind to their respective receptors to activate 
chloride-sensitive channel proteins positioned on the postsynaptic membrane and 
hyperpolarize neurons.  This inhibits electrical activity in nerve cells. 
Glycine is the simplest of all of the amino acids.  In addition to its many 
metabolic roles, it was shown to have depressant actions on spinal neurons in 1960 by 
Curtis and Watkins (Rajendra et al., 1997), and discovered to be a neurotransmitter in 
1965 by Aprison and Werman (Aprison, 1990).  When glycine is released from 
presynaptic sites onto glycine receptors on the postsynaptic membrane, the ion channels 
open.  This allows an influx of chloride and bicarbonate ions in adult neurons, 
hyperpolarizing the cell, and stabilizing the resting potential of the neuron. 
The glycine receptor (GlyR) and GABA receptor are highly homologous; 
however, GlyRs predominate in the spinal cord and brain stem, while GABA receptors 
are more abundant in the cortex and cerebellum (Langosch, 1995; Legendre, 2001). 
Along with their importance in the spinal cord, glycine receptors have been identified in 
many locations in the brain as well, including the cortex (Breustedt et al., 2004), retina 
(Pourcho and Goebel, 1990), central auditory system (Wenthold and Hunter, 1990), 
ventrolateral medulla (involved with respiration) (Ezure et al., 2003), hippocampus 
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(Chattipakorn and McMahon, 2002; Chattipakorn and McMahon, 2003), amygdala 
(McCool and Farroni, 2001), and ventral tegmental area (involved in reward) (Ye et al., 
1998a).  Glycine receptor β subunits are found in many regions with no known detectable 
α subunits (Betz, 1991; Legendre, 2001). Additionally, glycine receptor mRNAs have 
been localized in many other brain regions by in situ hybridization where functional 
glycinergic synapses have not yet been shown to exist (Legendre, 2001). 
 
1.4 Glycine Receptor Structure 
The glycine receptor is a membrane-bound protein composed of five subunits 
arranged around a central pore, with a stoichiometry of three α subunits and two β 
subunits in vivo (Betz, 1991).  Because of the glycine receptor’s high affinity binding to 
its competitive antagonist strychnine, GlyRs were the first of the Cys-loop proteins to be 
isolated from the nervous system of mammals (Bechade et al., 1994; Pfeiffer et al., 
1982).  To date, four alpha subunits (α1-α4) and one β subunit have been identified 
(Grenningloh et al., 1990; Legendre, 2001; Rajendra et al., 1997). 
The composition of GlyRs changes with development.  Embryonic GlyRs in 
immature neurons are predominantly α2 homomeric receptors, and the glycinergic 
synapses can be excitatory (Legendre, 2001; Takahashi et al., 1992; Tapia and Aguayo, 
1998).  In adults, glycine receptors are inhibitory and are most commonly composed of 
three α1 (each approximately 48 kDa) and two β subunit (each approximately 58 kDa) to 
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form a 250 kDa size protein (Betz, 1991).  This pentameric assembly was shown to be the 
most common composition in crosslinking studies (Langosch et al., 1988). 
Overall homomeric GlyRs form functioning receptors with properties similar to 
those of native, adult receptors making them useful for studies involving 
electrophysiology and mutagenesis (Mascia et al., 1996a).  When expressed in a 
heterologous system, such as the Xenopus laevis oocyte used in these studies, GlyR α1 




Figure 1.  Depiction of a glycine receptor.  Glycine receptors span the lipid bilayer and 
are composed of five subunits surrounding a central ion channel.  In Xenopus oocytes, 




Each α1 subunit is an integral membrane protein with four transmembrane 
segments (TM1-TM4).  Hydropathy analysis of the glycine receptor sequence predicted 
that these four hydrophobic segments spanned the membrane and had alpha helical 
conformations (Cascio, 2004).  Experiments involving mutagenesis of TM1-TM4 have 
supported this prediction.  Additionally, the recent cryo-electron micrograph data on the 
Torpedo nAChR provided good evidence for an alpha helical topology for all four 
segments (Miyazawa et al., 2003).  At present, the cryo-electron micrograph data is not 
high resolution, so questions remain over the exact positioning of the amino acids.  Also, 
whether the Torpedo structure can be applied, without modification, to every member of 
the cys-loop family remains to be demonstrated.  Because there is little sequence identity 
between nAcRs and inhibitory glycine and GABA receptors, even in the conserved 
membrane segments, it is possible that differences in structure exist within the receptor 
family. 
The TM2 domains form the wall of the anionic pore and is believed to be alpha 
helical in secondary structure (Legendre, 2001).  The alpha helical periodicity of TM2 is 
well characterized biochemically by use of probing with the substituted cysteine 
accessibility method (described in detail later).  These studies have shown periodic 
accessibility of thiol-specific reagents in nAChRs (Akabas et al., 1994; Wilson and 
Karlin, 2001; Zhang and Karlin, 1998) , GABAARs (Goren et al., 2004; Williams and 
Akabas, 1999; Xu and Akabas, 1996) and serotonin receptors (Panicker et al., 2002; 
Reeves et al., 2001).  This alpha helix has a kink due to a bulky, conserved leucine, which 
lines a critical part of the pore and is postulated to function as a pore blocking site and be 
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involved with receptor gating (Chang and Weiss, 1998; Chang and Weiss, 1999; Shan et 
al., 2002; Unwin, 1995; Unwin, 1998).  TM2 also contains other amino acids responsible 
for determining pore diameter and ion charge selectivity, and has rings of positively 
charged arginines and the top and bottom of the channel pore (Keramidas et al., 2000; 
Keramidas et al., 2002; Keramidas et al., 2004; Lee et al., 2003).  Ion charge selectivity is 
defined by the most intracellular section of TM2 of the glycine receptor, which also 
corresponds with the narrowest region of the ion channel pore (Keramidas et al., 2000; 
Keramidas et al., 2002; Keramidas et al., 2004; Lee et al., 2003).  An illustration of the 







Figure 2:  A schematic view of a glycine receptor membrane-spanning domain.  
Viewed from the extracellular surface of the cell, the receptor is composed of five 
subunits.  Each receptor subunit is believed to be a four-helical bundle in a clockwise in 
arrangement (the transmembrane segments are labeled 1-4).  The second transmembrane 






















As with other ion channels, GlyRs are not present in high quantities in mammals, 
in vivo.  While, nicotinic acetylcholine receptors can be isolated in enriched quantities 
from the electric organ of Torpedo electric fish (Unwin, 1998), there is no known natural, 
enriched source to isolate glycine receptor protein from for structural analysis (Cascio, 
2004).  Because of this, nAChRs have been better characterized than the other members 
of its subtype in the ligand-gated ion channel family.  For this reason, this family of 
receptors is sometimes referred to as the nicotinicoid receptors.  Recent work has 
progressed with overexpressing α1 glycine receptor subunits in insect cells infected with 
baculovirus (Cascio et al., 1993; Cascio et al., 2001; Morr et al., 1995).  As yet, a high-
resolution crystal structure of the protein is not available. 
The fact that we do not have high-resolution crystal structure data for the glycine 
receptor, or any other member of the ligand-gated ion channel family, leaves structural 
analysis in the realm of mutagenesis, biochemical manipulations and computer modeling.  
This has provided insight into details of the glycine receptor structure, and hopefully 
much of this data will be confirmed when a glycine receptor crystal structure is imaged. 
Each glycine receptor subunit has a large, extracellular, N-terminal region, four 
transmembrane segments, a large intracellular linker between TM3 and TM4, and a short, 
extracellular, C-terminal tail (Langosch, 1995) (Figure 3).
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Figure 3.  Schematic of a single glycine receptor α subunit.  Each glycine receptor 
subunit has a large, extracellular, N-terminal region, including the glycine binding site 
and two cys-loops (disulfide bound loops).  The protein chain crosses the membrane four 
times to give it four transmembrane segments.  There is a large intracellular linker loop 
between transmembrane segments three and four, and the C-terminal end of the protein is 
extracellular. 
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The N-terminal domain of the protein forms the ligand (glycine) binding domain.  
There are two highly conserved disulfide bonded loops which are important for the 
receptor function and which are involved with ligand binding (Rajendra et al., 1995).  
Because of the conservation of the cys-loops in these channels, this family is sometimes 
called “cys-loop” ion channels.  Uncoupling the first and second cysteine loop abolishes 
glycine receptor current, indicating that these loops play an important role in receptor 
stability and assembly (Rajendra et al., 1997).  Recently, the 2.7 Å structure of the 
acetylcholine binding protein was elucidated from crystallizing the protein from a 
freshwater snail (Lymnaea stagnalis) DNA library (Brejc et al., 2001).  This protein is a 
homopentamer, and each subunit is homologous to the N-terminal extracellular halves of 
the subunits of the ionotropic receptors (Brejc et al., 2001), thus providing structural 
details on the N-terminal domain.  Also, glycine’s competitive antagonist strychnine has 
a binding site near that of glycine (Vandenberg et al., 1992a; Vandenberg et al., 1992b). 
Much recent effort has focused attention on how the signal from ligand binding is 
transduced to the transmembrane regions and causes the pore to open.  Studies have 
found that the ligand binding domain has loops which interact with the linker region 
between TM2 and TM3 to couple agonist binding to the transmembrane domain (Kash et 
al., 2003).  The TM2-TM3 linker has also been shown to have increased accessibility as a 
result of channel gating (Lynch et al., 2001).  Still, the signal transduction mechanism 
from the point of glycine binding in the N-terminal region to the point of pore opening is 
not entirely understood. 
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Low expression of glycine receptors or receptors with reduced activity due to 
specific mutations cause channelopathies in humans, such as hyperekplexia (human 
startle disease) (Breitinger and Becker, 2002; Legendre, 2001).  Mutations resulting in 
startle disease have been identified in the TM1-TM2 intracellular loop, in TM2 and in the 
extracellular TM2-TM3 linker loop (Legendre, 2001; Rajendra et al., 1997; Schofield, 
2001). 
The large intracellular linker loop between TM3 and TM4 is the most diverse in 
terms of sequence between the LGICs.  The region is responsible for protein-protein 
contacts hypothesized to affect GlyR assembly, trafficking, clustering, targeting, turn-
over and modulation (Cascio, 2004).  It contains phosphorylation sites as well as a 
binding site for gephyrin.  Gephyrin is a cytoplasmic anchoring protein which was 
originally purified in the first isolation of the glycine receptor (Pfeiffer et al., 1982). 
Of interest here is the transmembrane domain of the GlyR α1 subunit, particularly 
the amino acids facing towards the center of each transmembrane helical bundle.  This is 
the region of the protein where alcohols and anesthetics are believed to bind and cause 
their actions. 
 
1.5 Drug Effects 
Glycine receptors are affected and modulated by a number of drugs including: 
alcohols (Aguayo and Pancetti, 1994; Celentano et al., 1988; Engblom and Akerman, 
1991; Engblom et al., 1996; Mascia et al., 1996a; Mascia et al., 1996b; Mihic, 1999; Ye 
et al., 2001a; Ye et al., 2001b), volatile and intravenous anesthetics (Yamakura et al., 
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2001) and inhalants (Beckstead et al., 2001; Beckstead et al., 2000).  Here, we are 
concerned with the effects of alcohols and volatile anesthetics.   
Clinically relevant concentrations of ethanol have been reported to potentiate the 
glycine receptor response in chick spinal cord neurons (Celentano et al., 1988), rat brain 
synaptoneurosomes (Engblom and Akerman, 1991), and cultured mouse hippocampal, 
cortical and spinal neurons (Aguayo and Pancetti, 1994; Aguayo et al., 1996).  
Experiments performed on developing rat hypoglossal motor neurons showed that 
glycine receptors composed of α2 subunits were less sensitive to ethanol than receptors 
composed of α1 subunits (Eggers et al., 2000). Experiments in the ventral tegmental area 
neurons of rats have shown differential results from cell to cell.  In 35% of cells, the 
glycine receptors were potentiated by ethanol (Ye et al., 2001a), and while in another 
45% of glycine receptors were inhibited by ethanol (Ye et al., 2001b). 
In heterologous expression systems (Xenopus laevis oocytes and HEK cells) the 
function of glycine receptors is also enhanced in the presence of clinically relevant 
concentrations of ethanol and longer chain alcohols (Krasowski and Harrison, 2000; 
Mascia et al., 1996a; Mascia et al., 1996b).  Since glycine receptors are mediators of 
inhibition in the spinal cord and in some areas of the brain, they are likely involved in the 
sedative and anesthetic effects of alcohol.  This hypothesis is supported by a study 
showing decreased alcohol effects in transgenic mice expressing a mutant, alcohol 
resistant, α1 subunit (Findlay et al., 2002). 
In the same way, volatile anesthetics have been shown to potentiate glycine 
receptors.  Experiments have shown that volatile anesthetics enhance glycine-activated 
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chloride currents of glycine receptors in rat medullary neurons (Downie et al., 1996), 
dissociated rat hippocampal neurons (Kira et al., 1998), as well as in recombinant 
systems with transiently transfected cells (Harrison et al., 1993) and in Xenopus oocytes 
(Downie et al., 1996).  Analysis of current data showed that the glycine receptor is one of 
the most credible candidates for mediating immobility caused by volatile anesthetics 
(Sonner et al., 2003).  Both alcohols and volatile anesthetics enhance glycine receptors in 
a concentration dependent manner and shift the glycine concentration response curve to 
the left, without altering the maximal glycine response (Legendre, 2001). 
 GABA ρ1 receptors share sequence homology with GlyRs, and like GlyRs, they 
may be expressed homomerically.  There exists a noteworthy difference between these 
two receptors:  homomeric GABA ρ1 receptors are inhibited by ethanol, while 
homomeric GlyRs are enhanced by ethanol.  Taking advantage of this difference, 
chimeric receptors were created using the sequences of both, leading the way to 
identifying the site of alcohol action on the glycine receptors (Mihic et al., 1997).  
Stemming from these studies, two amino acids were determined to be critical for alcohol 
and anesthetic action on the glycine receptor (as well as the homologous residues in the 
GABAA receptor), a site in TM2 (S267), as well as a residue in TM3 (A288) (Mihic et 
al., 1997).  Mutations in homologous positions in different GABAA receptor subunits 
reduced ethanol potentiation when the mutations were in either the α2 or the β1 subunits, 
but the same mutations in the γ2L subunit had no effect (Ueno et al., 1999). 
 Mutagenesis at S267 showed that ethanol was only able to potentiate the glycine 
receptor if serine was replaced with a small amino acid, while substitution of larger 
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amino acids (such as valine) resulted in no effect, and substitution of even larger amino 
acids (such as tyrosine) resulted in inhibition (Ye et al., 1998b).  Mutagenesis of A288 
showed that the molecular volume of this position is negatively correlated with 
potentiation by volatile anesthetics (Yamakura et al., 1999).  Exchange of the amino acids 
at these sites in TM2 and TM3 between the homomeric GABA ρ1 and Gly α1 receptors 
switched the alcohol cutoffs in both receptors, suggesting that these residues controlled 
the size of an alcohol binding cavity (Wick et al., 1998).    Also, coupling mutagenesis of 
the homologous critical positions (S270 and A291, along with the TM1 site L232) in the 
GABAA receptor and using volatile anesthetics of different sizes allowed for an estimate 
of the size of the cavity (Jenkins et al., 2001).  These pieces of evidence suggest that 
amino acids in TM1, TM2 and TM3 are a part of a single alcohol and volatile anesthetic 
binding cavity.  
 Experiments on a constitutively active mutant receptor showed that ethanol and 
volatile anesthetics affect channel opening independent from ligand binding (Beckstead 
et al., 2002).  A recent study that used increased atmospheric pressure as an antagonist of 
ethanol’s actions suggested that there were multiple sites of ethanol action on the glycine 
receptor (Davies et al., 2004).  While one site seems to be located in the most 
extracellular section of the transmembrane region, a second site may exist in the amino-
terminus (A52) (Davies et al., 2004; Mascia et al., 1996b).  Here, the focus was on the 




1.6 SCAM and the MTS Reaction 
Methanethiosulfonate (MTS) reagents and other thiol-specific compounds have 
been used for various purposes.  Some are used as blocking, affinity labeling and reporter 
groups.  Others may also be used as crosslinkers and as chemical modifiers of peptides 
and proteins (Dime, 1997).  There are many differently sized, shaped and charged thiol-
specific reagents available.  Those used in the present studies included neutral alkyl MTS 
reagents of various carbon chain lengths, ranging from methyl MTS to hexadecyl MTS, 
as well as benzyl MTS and pCMBS-. 
The substituted cysteine accessibility method (SCAM) couples site-directed 
mutagenesis and biochemical probing with MTS compounds.  SCAM uses MTS reagents 
to explore the local environment of specific positions in receptors and to reveal 
environmental changes under different conditions (Karlin and Akabas, 1998).  For 
example, SCAM allows changes in specific positions to be examined in the presence and 
absence of agonist or drug molecules.  In electrophysiological experiments, reaction is 
measured by a change in the properties of the receptor after reaction, as a change in 
current. 
Reaction with a cysteine occurs or does not occur, which can indicate distinct 
changes in local environment and accessibility to a specific position.  Reaction also may 
occur at different rates.  In these cases, reaction occurs more quickly at one position than 
another.  The comparison of the reaction rates between different substituted cysteines can 
provide information about the local environment of a position in a protein.  In particular, 
reaction depends upon two factors: accessibility and reactivity.  Accessibility depends on 
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the access pathway from the bath solution to the cysteine and the steric and electrostatic 
factors encountered by the MTS molecule (Bali and Akabas, 2004; Karlin and Akabas, 
1998).  Reactivity depends upon the local environment surrounding the substituted 
cysteine, including the ionization state, the local electrostatic potential, the amount of 
time spent in the water-accessible surface and local steric changes at the cysteine (Karlin 
and Akabas, 1998). 
If the MTS molecule is able to reach the substituted cysteine, then reaction of 
MTS requires that the sulfhydryl side chain of the cysteine is ionized and reactive.  
Ionization occurs predominantly in the presence of water.  In the ionized state, the 
cysteine and MTS molecule can covalently react to label the cysteine, and reaction is at 
least 5 X 109 faster with an ionized –S- than with an un-ionized –SH (Karlin and Akabas, 
1998).  Meanwhile, on the lipid-accessible surface and in the protein interior, the 
dielectric constant for the environment is low, and ionization and MTS reaction are rare 
(Karlin and Akabas, 1998).  Also produced in the reaction are sulfinic acid (which 
decomposes rapidly to low molecular weight, volatile products that do not affect receptor 
function) and water (Dime, 1997).  MTS reaction with a cysteine indicates that the 






Figure 4. Methanethiosulfonate (MTS) reaction scheme.  MTS reagents are 
sulfhydryl-specific compounds. In the presence of water, the amino acid cysteine is often 
in the ionized state with water removing a hydrogen atom from the cysteine side chain.  
In the ionized state, the cysteine and MTS molecule can covalently react to label the 
cysteine.  Also produced in the reaction are sulfinic acid and water.  MTS reaction with a 
cysteine indicates that the cysteine at a particular position is water-accessible. 
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The key question of whether S267C was important to the action of alcohols and 
anesthetics and part of a binding pocket was addressed by Mascia et al. (2000).  
Following mutation of a target GlyR amino acid residues to cysteine (S267C), an alkane 
thiol anesthetic or varieties of methanethiosulfonate compounds were used to covalently 
label this binding site (Mascia et al., 2000).  By creating a method to covalently bind a 
drug molecule to the putative binding site, the receptor function was irreversibly 
enhanced.  Also, the usual ability of octanol and isoflurane to enhance the receptor 
function was lost, indicating the action of alcohols and anesthetics stems from binding at 
a single binding pocket (Mascia et al., 2000). 
 The following dissertation branches from this work.  Particularly, it aims to 
answer the questions of which other amino residues are involved in the binding pocket, 
how they are oriented with respect to one another and the relationship between binding 
and accessibility and receptor function. 
 
1.7 Dissertation Aims 
Overall Hypothesis and Goal:  The overall experimental plan is to structurally 
characterize the alcohol and volatile anesthetic binding site in the human glycine 
receptor.  Particularly, the experiments will provide information concerning which 
residues contribute to the binding site, how the volume of the site changes with receptor 
gating, and the distance separating specific residues within the binding site itself.  These 
results will contribute to an updated molecular model of the alcohol/anesthetic binding 
site and understanding of the mechanism by which drugs bind to it and affect it. 
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This plan includes three main aims: 
 
Aim 1: To determine whether TM2 residue S267 and TM3 residue A288 face one 
another in three-dimensional space.  Is an alcohol and volatile anesthetic binding pocket 
formed by residues in TM2 and TM3? 
Aim 2: To determine whether the volume of this binding pocket differs when the channel 
is open in contrast with the size when the channel is closed.  Do drugs stabilize the open 
state of the glycine receptor because of the volume they occupy in the drug binding 
cavity? 
Aim 3: To determine whether amino acid residues in transmembrane segments 1 and 4 
contribute to the alcohol and volatile anesthetic binding pocket. 
 
1.8 Chapter Overview 
Chapter 2 contains the experimental methods used to complete the aims studied.  
These include mutagenesis, Xenopus oocyte expression and two-electrode voltage clamp 
electrophysiology.  It also describes the crosslinking and substituted cysteine accessibility 
experiments in full and the statistical analyses used. 
Chapter 3 answers the questions posed in Aim 1 of my proposal.  Intrasubunit 
contact points between the four transmembrane segments of ligand-gated ion channel 
subunits have not been defined experimentally.  We tested whether two amino acids in 
TM2 (S267) and TM3 (A288), known to be critical for alcohol and volatile anesthetic 
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action, could crosslink by mutating both to cysteines and expressing the receptors in 
Xenopus laevis oocytes.  In contrast with the wild type receptor and single cysteine 
mutants, the S267C/A288C double mutant displayed unusual responses including a tonic 
leak activity that was closed by strychnine and a run-down of the response upon repeated 
applications of glycine.  We hypothesized that these characteristics were due to 
crosslinking of the two cysteines on opposing faces of these adjacent, alpha helical TMs.  
This would alter the movement of these two regions required for normal gating.  To test 
this hypothesis, we used dithiothreitol to reduce the putative S267C-A288C disulfide 
bond.  Reduction abolished the leak current and provided normal responses to glycine.  
Subsequent application of the crosslinking agent mercuric chloride caused the initial 
characteristics to return.  Our evidence of disulfide formation between these two 
introduced cysteines defines the vertical position of TM3 with respect segment TM2, and 
shows that they face each other.  This provides an improved model of orientation of these 
two TM segment and gives us some insight towards the location and role of the TM2-
TM3 interface.  Constraining this dynamic region of the glycine receptor with a disulfide 
bond, results in channels that cannot function normally.  To our knowledge, this was the 
first demonstration of intrasubunit cross-linking of transmembrane segments in a ligand-
gated ion channel. 
Chapter 4 focuses on a question posed in Aim 3 of my proposal.  A single amino 
acid (I229) in TM1, evidenced to be of interest in anesthetic action, was studied.  This 
amino acid was mutated to cysteine and probed for reaction with sulfhydryl-specific 
reagents.  I229C showed state-dependent reaction with MTS only in the presence of 
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agonist, indicating that the position is located in a water-filled environment.  The effects 
of alcohols and anesthetics were determined for this mutant, and the ability of MTS 
reagents to interfere with drug binding was also examined. 
Chapters 5 and 6 focus on Aim 2 of my dissertation proposal.  The glycine 
receptor is a target for both alcohols and anesthetics, and certain amino acids in the α1 
subunit transmembrane segments are critical for drug effects.  Introducing larger amino 
acids at these positions increases the potency of glycine, suggesting that introducing 
larger residues, or drug molecules, into the drug-binding cavity facilitates channel 
opening.  A possible mechanism for these actions is that the volume of the cavity expands 
and contracts during channel opening and closing.  To investigate this hypothesis, 
mutations for amino acids in TM2 (G256C, T259C, V260C, M263C, T264C, S267C, 
S270C) and TM3 (A288C) were individually expressed in Xenopus laevis oocytes.  The 
ability of sulfhydryl-specific alkyl methanethiosulfonate (MTS) compounds of different 
lengths to covalently react with introduced cysteines in both the closed and open states of 
the receptor was determined.  S267C was accessible to short chain (C3-C8) MTS in both 
open and closed states, but was only accessible to longer chain (C10-C16) MTS 
compounds in the open state.  Reaction with S267C was faster in the open state.  A288C 
showed state-dependent reaction with MTS, and reacted only in the presence of agonist.  
Additionally, reaction of A288C with propyl MTS blocked further potentiation by 
isoflurane, providing strong support that A288C is contributing to a binding site for 
alcohols and anesthetics.  M263C and S270C were also accessible to MTS labeling.  
Mutated residues more intracellular than M263C did not react, indicating a floor of the 
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cavity.  These data demonstrate that the conformational changes accompanying channel 
gating increase accessibility to amino acids critical for drug action in TM2 and TM3, 
which may provide a mechanism by which alcohols and anesthetics can act on glycine 
(and likely other) receptors. 
Chapter 7 focuses on a question posed in Aim 3 of my proposal.  A cysteine scan 
was completed for twelve amino acids of the TM4 domain.  Each amino acid in this 
region was mutagenized to cysteine and tested for water-accessibility by probing these 
positions with sulfhydryl-specific reagents.  Four mutants (W407C, I409C, Y410C and 
K411C) showed water-accessibility and irreversible changes in receptor function 
following reaction with propyl MTS.  Since these native amino acids may be located in a 
water-filled environment, they may also be participants in the alcohol/anesthetic binding 
pocket.  The effects of alcohols and anesthetics were determined for these mutants, and 
the ability of MTS reagents to interfere with drug binding was also examined. 
Chapter 8 includes an overall discussion of these data and the conclusions that 
may be derived from these experiments.
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2.0 Materials and Methods 
 
2.1 cDNA Preparation and Site-Directed Mutagenesis 
 These studies used cDNAs encoding the wild type, human α1 glycine receptor 
previously subcloned in the pBK-CMV N/B-200 vector.  In order to introduce missense 
mutations into the receptor sequence, site-directed mutagenesis will be carried out using 
the Stratagene QuikChangeTM Site-Directed Mutagenesis Kit (LaJolla, CA).  Mutagenesis 
was also carried out on GlyR α1(S267C) cDNA subcloned previously in the laboratory in 
the pCIS2 vector.  Mutagenic sense and antisense primers were designed for each desired 
mutation and ordered from Integrated DNA Technologies, Inc. (Coralville, IA).  Partial 
sequencing of the mutated regions was performed by The University of Texas at Austin’s 
Core Sequencing Facility to verify all introduced mutations.  cDNA was purified and 
prepared using a QIAGEN mini- or maxi-prep kit (Valencia, CA) prior to injection. 
 
2.2 Isolation and Injection of Xenopus laevis Oocytes 
 Xenopus laevis frogs (from NASCO International, Fort Atkinson, WI and 
Xenopus Express, Plant City, FL) were housed in static aquarium tanks at 19-21°C with a 
12/12 hour light/dark cycle.   They were fed fishmeal or frog brittle 2-3 times per week.  
Before surgery, the frogs were anesthetized.  Then a small incision was made in the 
abdominal wall and a small piece of ovary was excised. 
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Stage V and VI oocytes were isolated by removing the inner ovarian epithelium 
layer and theca layers manually with forceps in hypertonic isolation media (108 mM 
NaCl, 2 mM KCl, 1 mM EDTA, and 10 mM HEPES, pH 7.5), which cause the oocytes to 
shrink from the encapsulating membranes. Oocytes were then treated with collagenase 
solution for 10 minutes following isolation to remove the follicular cell layer of the 
oocytes. Collagenase solution is composed of 0.5 mg/ml of Sigma type IA collagenase in 
collagenase buffer (83 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.5). 
The oocytes were removed to incubation medium for injection with cDNAs.  Incubation 
media consists of filtered Modified Barth’s solution (MBS; containing 88 mM NaCl, 1 
mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM MgSO4, 0.33 mM Ca(NO3)2 and  
0.91 mM CaCl2) that is supplemented with 10mg/l streptomycin, 10,000 units/l of 
penicillin, 50 mg/l of gentamicin, 90 mg/l theophylline and 220mg/l pyruvate. 
The wild type and mutant α1 glycine receptor subunit cDNAs (1.0 ng/30nl) were 
injected into the nucleus of oocytes located at the pole of the animal hemisphere.  
Colman’s “blind” method was used to perform for nuclear injection of cDNAs (Colman, 
1984).  cDNAs were injected using a microdispenser (Drummond Scientific, Broomwall, 
PA) and needles pulled with a flaming/brown micropipette puller (Sutter Instrument Co., 
Novato, CA) and cut to a diameter of 10-20 µM.  Following injections, oocytes were 
placed singly in 96 well plates (Corning Glass Works, Corning, NY) containing 
incubation media and incubated at 15°C.  Following incubation, electrophysiological 
recordings were made in the oocytes 1 to 12 days after injection (Figure 5).
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Figure 5.  Isolation and injection of Xenopus laevis oocytes.  Oocytes were isolated 
from female Xenopus laevis frogs, injected with cDNAs encoding the GlyR α1 subunit, 




When expressed in a heterologous system, such as Xenopus laevis oocytes, GlyR 
α1 subunits can assemble homomerically to form functioning receptors with properties 
like those of native receptors (Taleb and Betz, 1994).  In the accessibility experiments 
with sulfhydryl specific reagents, wild type GlyR α1 cDNAs were injected and studied 
along with following α1 subunit mutants:  I229C, G256C, T259C, V260C, M263C, 
T264C, S267C, S270C, and A288C.  In the crosslinking studies, the following α1 subunit 
mutant receptors were injected in addition to the wild type:  S267C, A288C, S267C + 
A288C in a 1:1 ratio, S267C/A288C, S270C/I285C, and M263C/L291C cDNAs. 
 
2.3 Electrophysiological Recording 
 Electrophysiological recordings were made in the oocytes 1 to 12 days after 
injection.  All experiments were performed at room temperature (20-22˚C).  Oocytes 
were placed in a depression in the center of a rectangular chamber (approximately 100 µl 
volume), impaled in the animal pole with two glass electrodes (0.5-10 megaohm) filled 
with 3 M KCl, and clamped at a voltage of -70 mV using a Warner Instruments OC725C 
(Hamden, CT) oocyte clamp.  The oocytes were perfused with filtered Modified Barth’s 
solution (MBS) containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 
0.82 mM MgSO4, 0.33 mM Ca(NO3)2 and  0.91 mM CaCl2.  The perfusion rate was 2.0 
ml/minute and controlled by a peristaltic pump (Cole-Parmer Instruments Co., Chicago, 
IL) through 18-gauge polyethylene tubing (Becton Dickinson, Sparks, MD).  The oocytes 
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were tested for expression by measuring whether a current was elicited by application of 
glycine dissolved in MBS.  Oocytes expressing the injected receptors were used in the 
following experiments and currents were continuously plotted using a Cole-Parmer chart 
recorder (Vernon Hills, IL). 
 Concentration response curves were determined for the wild type and each mutant 
receptor studied.  Concentrations of glycine, usually ranging from 10 µM – 1 mM, were 
applied at 10-15 minute intervals in order of increasing concentration until a plateau was 
reached.  For sensitive receptors, even lower concentrations were tested, and for less 
sensitive receptors, higher concentrations of glycine were used to reach a plateau.  Curves 
were analyzed using GraphPad Prism as described in chapter 2.7.  The concentration of 
glycine producing the greatest response in the concentration response curves was used to 
elicit the maximal glycine response in subsequent experiments. 
 
2.4 Crosslinking Transmembrane Segments 2 and 3 
Glycine (1 mM) was dissolved in MBS and applied for 20 s (30 s for lower 
concentrations).  Dithiothreitol (DTT) was freshly prepared and dissolved in MBS at a 
concentration of 1 mM or 10 mM prior to each three-minute application.  Mercuric 
chloride (HgCl2; 10 µM) was prepared from a 1 mM stock in MBS and applied to 
crosslink (Soskine et al., 2002) for one minute.  Strychnine (10 µM) was prepared from a 




2.4.1 Reduction and Crosslinking Experiments 
 Reduction experiments were performed as follows:  1 mM glycine was applied to 
the oocytes followed by a washout of 15 minutes.  This was repeated twice.  Then the 
oocyte was unclamped during the 1 mM DTT application because DTT affected the bath 
electrodes or impaling electrodes, causing the oocyte clamp to be unable to maintain the -
70 mV potential in the mutant, WT and uninjected oocytes.  The oocyte was reclamped, 
and was washed for 15 minutes.  Glycine was then reapplied three times with 15 minute 
washouts with the last response to glycine being measured 45 minutes after DTT.  The 
reduction and crosslinking experiments were performed as follows:  Glycine (1 mM) was 
applied to the oocyte, followed by a 15 minute washout.  This was repeated once.  This 
was followed by reduction with 10 mM DTT (oocyte unclamped) and a 15 minute 
washout.  Glycine was reapplied with a 15 minute washout.  Then the oocyte was 
unclamped again during a 1 minute application of 10 µM HgCl2 for crosslinking.  
Glycine was reapplied with a 15 minute washout.  This was followed by a second 
reduction with DTT and 15 minute washout (as above) and a final application of glycine. 
 
2.4.2 Drug Responses in Reduced and Crosslinked Receptors 
Ethanol (100 mM), octanol (115 µM), isoflurane (0.8 mM), and chloroform (2.0 
mM) were dissolved in MBS immediately prior to each experiment.  Responses to these 
concentrations of alcohols and anesthetics were tested (following a 1 minute 
preincubation with the drug alone) on an EC5-10 of glycine (concentration of glycine 
eliciting 5-10% of the maximal glycine response), which was determined individually for 
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each oocyte.  S267C/A288C mutants were tested for their drug responses in the 
crosslinked state before DTT application.  After reduction of S267C/A288C with 1 mM 
DTT, the EC5-10 concentration of glycine was re-determined for each oocyte, and the 
drugs were tested in the same manner.  The drug responses were measured approximately 
45 minutes after reduction to ensure that most receptors were uniformly in the reduced 
form. 
 
2.5 Experiments Using Sulfhydryl-Specific Compounds 
  
2.5.1 Accessibility 
First the EC5-EC10 of glycine (5-10% of the maximal response to 1 mM glycine) 
was determined for each expressing oocyte.  After a 10 minute washout, MTS reagents 
were applied in either the absence of glycine (closed state) or in the presence of 1 mM 
glycine (open and desensitized states).  Then responses to the initial EC5-10 of glycine 
were determined at timepoints 10, 20 and 30 minutes after application of MTS.  The 
percent potentiation of the recorded glycine current over the initial current before the 





Figure 6.  An example tracing of MTS application procedure.  This tracing shows 
S267C reaction with 50 µM propyl MTS.  An EC5-EC10 glycine (5-10% of the maximal 
response to 1 mM glycine) was determined for each expressing oocyte.  The first 
maximal glycine response is not shown.  After a 10 minute washout, propyl MTS was 
applied in either the absence of glycine (closed state) as shown above, or in the presence 
of 1 mM glycine (open and desensitized states).  The initial EC5-10 of glycine was 




 Wild type and mutant receptors were perfused for 90 s with a 50 µM solution of 
either propyl MTS, hexyl MTS, octyl MTS, decyl MTS, dodecyl MTS, hexadecyl MTS, 
benzyl MTS or para-chloromercuribenzene sulfonate (pCMBSֿ) in either the absence of 
glycine or in the presence of 1 mM glycine.  In testing these differently sized MTS 
compounds for labeling in the open and the closed states, information about the 
accessibility and volume of this portion of the binding pocket can be better appreciated.  
All MTS applications were for 90 s, unless otherwise specified as this gave a steady-state 
reaction with S267C.  MTS compounds were dissolved in dimethyl sulfoxide (DMSO) 
and diluted in MBS to a final DMSO concentration not exceeding 0.05% (for hexadecyl 
MTS the final concentration was 0.1%).  These concentrations of DMSO did not affect 
GlyR function.  MTS solutions were prepared immediately before application to prevent 
degradation in all experiments (unless otherwise noted). 
For some mutants, the maximal glycine response required a higher concentration 
of glycine from the concentration response curve data.  In these cases, higher 
concentrations of glycine were used for co-application with MTS reagents.  For G256C, 
T259C, V260C, and A288C, 10 mM glycine was used as the maximum glycine 
concentration for labeling and to determine the EC5-10.  For Y410C, 5 mM glycine was 
used as the maximal glycine concentration.  During co-applications of MTS reagents with 
maximal glycine, the voltage clamp circuit on the oocyte was inactivated to prevent cell 
damage and run down of the glycine current.  
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2.5.2 Testing for Silent Reaction of MTS 
To detect whether decyl MTS was reacting “silently” with S267C, but producing 
no observable change in current, the EC5-10 of glycine was determined, and an application 
100 µM decyl MTS (in MBS) was followed by measurement of the glycine response.  
This was followed by an application of 50 µM propyl MTS (in MBS) and measurement 
of the glycine response.  Responses to the initial EC5-10 of glycine were measured 10 
minutes after each MTS application.  We also tested the stability of propyl MTS in room 
temperature MBS.  We observed no change in effectiveness of 1-hour-old 50 µM propyl 
MTS solutions compared with freshly prepared solutions on S267C. 
 
2.5.3 MTS Concentration Response Curves for S267C 
Concentration response curves for propyl and decyl MTS in the presence and 
absence of glycine were determined for irreversible enhancement of S267C.  Different 
oocytes were used for each concentration (n = 4-11 oocytes per concentration point).  For 
each oocyte (at ten minute intervals):  the EC5-10 of glycine was determined, the MTS 
compound was applied for 90 seconds, and the original EC5-10 of glycine was re-applied.  
Concentrations ranging from 1-1000 µM of propyl MTS and concentrations ranging from 




2.5.4  Rate of Reaction with MTS in the Presence and Absence of Glycine and/or 
Anesthetics 
The rate of reaction of propyl MTS (50 µM) with S267C was determined in four 
conditions: 1) no glycine, 2) no glycine plus 0.6 mM isoflurane, 3) 1 mM glycine and 4) 
1 mM glycine plus 0.6 mM isoflurane.  For conditions 1 and 3, the EC5-10 of glycine was 
first determined for each oocyte.  After 10 minutes, propyl MTS (50 µM) was applied for 
15 s in the absence of glycine (10 s applications in the presence of glycine because the 
cumulative reaction time was shorter).  Ten minutes following the propyl MTS 
application (or 15 min for MTS applications with glycine to allow time for receptor 
recovery from desensitization), the original EC5-10 of glycine was re-applied.  This 
procedure was repeated until the glycine response reached a steady-state.  For conditions 
2 and 4, the application procedure was identical and 0.6 mM isoflurane was co-applied 
with propyl MTS in the presence and absence of glycine.  All MTS and isoflurane 
solutions were prepared immediately before each application to ensure that a uniform 
concentration of these compounds reached the oocytes.   
Currents were normalized using the following procedure to put each ooctye’s 
response on a scale of 0 (initial current) to 1.0 (steady-state current).  For each oocyte, all 
currents were divided by the initial current.  Then 1 was subtracted from all of the values.  
These normalized responses for each oocyte were fit to a one phase exponential 
association curve to determine the time and rate constants of each curve.  These time 
constants were then averaged and presented with their standard errors and the second 
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order rate constants were calculated by dividing the averaged rate constants by the 
concentration of MTS applied. 
The rates of reaction of hexyl and decyl MTS with S267C were determined in the 
same manner.   Ten second applications of 50 µM hexyl MTS were applied in the closed 
state, and 10 s applications of 5 µM hexyl MTS (or 1 µM decyl MTS) were applied in the 
presence of 1 mM glycine until a steady state response was reached.  Additionally, the 
reaction rate constant for the reaction of propyl MTS (500 µM) with A288C was 
determined in the presence of 1 mM glycine. 
 
2.5.5 Differentiating Reactive Receptor States 
To differentiate the receptor states MTS reacts with, the potentiation by 0.8 mM 
isoflurane was measured following decyl MTS reaction with S267C receptors in the 
closed (as a control), desensitized and open/desensitized states.  The isoflurane 
potentiation of the EC5-10 glycine current was measured for each condition and compared 
to that of unlabeled receptors.  As shown previously, receptors that could be labeled by 
MTS would have eliminated or reduced isoflurane potentiation (Mascia et al., 2000).  
Receptors were labeled (90 s) in the closed state (50 µM decyl MTS) and 
open/desensitized state (50 µM decyl MTS + 1 mM glycine).  Desensitized receptors 
were labeled after a 10-14 minute application of 1 mM glycine that left only 1-5% of the 
maximal current activatable.  Then the oocyte was washed in MBS (30 s), followed by 
application of 50 µM decyl MTS in MBS to label in either the desensitized or closed 
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state.  For all of the above conditions, the isoflurane potentiation was determined 15 
minutes after MTS labeling.  Potentiation was calculated by dividing the drug-induced 
current by the average EC5-10 glycine-induced currents applied 10 minutes before and 
after each drug application.  For the control, unlabeled receptors, the isoflurane 
potentiation was determined as above.  Isoflurane was dissolved in MBS or glycine 
solutions immediately prior to each experiment.  Samples of bath solutions of isoflurane 
reaching the oocyte were measured by gas chromatography to have a 50% loss from the 
prepared vial solutions.  Thus, we prepared a vial solution of 1.6 mM to produce a bath 
concentration at the oocyte of 0.8 mM isoflurane (approximately 2.4 times the anesthetic 
EC50) (Franks and Lieb, 1994). 
 
2.6 Chemicals and Reagents 
 Glycine was purchased from Bio-Rad (Hercules, CA).  All sulfhydryl-specific 
reagents were purchased from Toronto Research Chemicals (Toronto, Ontario).  
Isoflurane was purchased from Ohmeda Caribe Inc. (Liberty Corner, NJ) and Marsam 
Pharmaceuticals, Inc. (Cherry Hill, NJ).  Ethanol was purchased from AAPER Alcohol 
and Chemicals Co. (Shelbyville, KY).  Dithiothreitol, mercuric chloride, strychnine, 
octanol, chloroform and all other electrophysiological reagents were purchased from 
Sigma Chemical Co. (St. Louis, MO). 
 
2.7 Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism 3.02 and 4.0 (San 
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Diego, CA).  The software was used to fit concentration response curves with non-linear 
regression curve fitting for a sigmoidal dose-response curve with a variable slope.  Wild 
type and mutant EC50 and Hill coefficients were compared using one-way ANOVA with 
the Dunnett’s post-test.  Additionally, it was used to define significance of the glycine 
responses measured, either following MTS reagent applications or responses modulated 
by drugs, versus the control EC5-10 glycine responses using the paired Student’s t-test.  
For the rate of reaction experiments, the response of each oocyte was fit to a one phase 
exponential association curve to determine the time and rate constants.  These values 
were averaged and presented with their standard errors. 
 
2.8 Molecular Volume Calculations and Modeling 
 All molecular modeling was carried out by Dr. James R. Trudell of Stanford 
University School of Medicine who was a collaborator on this project, a co-author of the 
resulting publications and a member of my thesis committee.  The volumes of the MTS 
reagents, the volumes of the corresponding alkyl thiols that functionally react with the 
substituted cysteine residue, and the volumes of the amino acids cysteine and serine were 
calculated using Spartan 5.0 (Wavefunction, San Diego, CA). 
Molecular modeling of the glycine receptor transmembrane region was conducted 
as previously described (Trudell and Bertaccini, 2004).  A model of the four 
transmembrane segments of a glycine receptor was built by threading the primary 
sequence of GlyR α1 over a template of a four-helix bundle found in the high-resolution 
structure of the cytochrome C oxidase (Protein Data Bank code 20CC).  An initial 
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constraint on the model was that amino acid residues known to modulate anesthetic 
potency were in direct proximity to one another [I229 (TM1), S267 (TM2), and A288 
(TM3)].  A second set of constraints was that the pore-facing and lipid-facing residues 
identified in the literature should have appropriate positions.  This model was used to 
examine the proximity or S267C and A288C, and also to predict nearby residues to S267, 
as described below. 
The model was used to examine whether crosslinking between S267C and A288C 
was possible.  This molecular model positioned S267C and A288C in proximity to form a 
disulfide bond.  Residues S267 and A288 were replaced with cysteines and an S-S bond 
was formed between them.  All backbone atoms (C, Ca, N, O) were tethered to their 
initial positions with a force constant of 100kcal/A2 and the structure was subjected to 
restrained molecular mechanics optimization with the CFF91 force field using Insight II 
(v 2000.1, Accelrys, San Diego, CA). 
Additionally, the model revealed that other residues in TM2 might be in 
proximity to S267 and could be accessible to MTS reagents (G256, T259, V260, M263, 
T264, S270).  The positioning of hexyl MTS was based on forming the disulfide bond 
and then re-optimizing the GlyR model with harmonic restraints (100 kcal/Å2) on all the 
backbone atoms of the subunit to illustrate a likely orientation and show the scale of the 
molecule relative to the subunit.
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3.0 Orientation of Transmembrane Segments 2 and 3 
 
Portions of this chapter were published in an article in Journal of Neurochemistry in 
August 2004 and are reprinted with permission.  © Journal of Neurochemistry, 
International Society for Neurochemistry and Blackwell Publishing 
 
Lobo IA, Trudell JR, Harris RA.  Cross-linking of glycine receptor transmembrane 
segments two and three alters coupling of ligand binding with channel opening. J 




Strychnine sensitive glycine receptors (GlyRs) are a member of a family of 
ligand-gated ion channels.  Receptors of this family are arranged as five subunits 
surrounding a central pore with each subunit composed of four alpha helical 
transmembrane segments (TM1-TM4) (Miyazawa et al., 2003; Rajendra et al., 1997).  
Miyazawa et al. recently extended the resolution of the homologous Torpedo 
acetylcholine receptor to 4 Å, showing an inner ring of TM2 alpha helices line the 
channel pore with a second outer ring formed by the 15 alpha helices of TM1, 3 and 4 
(Miyazawa et al., 2003). 
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 Sites of alcohol and volatile anesthetic action on the glycine receptor (and the 
homologous GABAA receptor) have been identified:  in TM1 (I229), TM2 (S267), as 
well as a residue in TM3 (A288) (Greenblatt and Meng, 1999; Jenkins et al., 2001; Mihic 
et al., 1997; Ueno et al., 1999; Wick et al., 1998; Yamakura et al., 1999; Ye et al., 
1998b).  These amino acids have been hypothesized to line a binding pocket for alcohols 
and volatile anesthetics between the four transmembrane segments of each subunit  
(Jenkins et al., 2001; Mascia et al., 2000; Yamakura et al., 2001).  Though the pore lining 
residues of TM2 have been defined by cysteine substitution and labeling in this family of 
proteins (Horenstein et al., 2001; Xu and Akabas, 1996; Zhang and Karlin, 1998), the 
contact points between the non-pore lining TM2 residues that may face TM1, 3 or 4 are 
undetermined.  Considering that these amino acids are distant from one another in the 
primary amino acid sequence and that there is no complete crystal structure available for 
the glycine receptor, we were interested in determining how these amino acids were 
arranged. 
Currently, there are two pieces of experimental evidence that suggest S267 and 
A288 may be near one another from data gathered in homologous receptors.  First, Wick 
et al. exchanged amino acids in TM2 and TM3 between the homomeric GABA ρ1 and 
GlyRs to alter alcohol cutoffs of these two receptors.  The alcohol cutoff is the point at 
which increasing the length of the alkyl chain of a primary alcohol no longer produces an 
increase in potency.  The homomeric GlyR α1 has an alcohol cutoff at decanol, while the 
GABA ρ1 receptor cutoff is at heptanol, suggesting that the GABA ρ1 alcohol binding 
pocket is smaller than that of the GlyR.  When homologous positions of GABA ρ1 (I307 
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and W328) were converted to their smaller glycine receptor counterparts (S267 and 
A288), the alcohol cutoff of the single mutant receptors increased from 7 to 9.  Mutation 
of both of these amino acids to I307S/W328A increased the alcohol cutoff to be 
dodecanol or higher, suggesting that both residues were a part of a single alcohol binding 
cavity (Wick et al., 1998).    Secondly, Jenkins et al. studied homologous positions of the 
GABAA receptor, S270 and A291, and replaced them with the bulky amino acid 
tryptophan.  The S270W single mutant was insensitive to the anesthetics isoflurane and 
halothane, but retained sensitivity to the smaller anesthetic chloroform.  Meanwhile, 
when both were replaced to create a S270W/A291W double mutant, the receptor was 
insensitive to chloroform as well as isoflurane and halothane  (Jenkins et al., 2001).  
Here, we tested for a direct association of the GlyR α1 amino acids positions S267 and 
A288 to determine the orientation of TM2 and TM3. 
 Crosslinking has been used for decades to gather structural information about 
proteins.  Existing and introduced cysteines have been crosslinked to determine near-
neighbor relationships and associations of proteins, orientations of interactions as well as 
the activity, folding and three-dimensional structures of diverse proteins.  In the GABAA 
receptor, crosslinking was used recently to identify extracellular domain residues that 
interact with the TM2-TM3 linker loop to couple agonist binding and gating (Kash et al., 
2003), and to determine intersubunit TM2 segment contact points (Horenstein et al., 
2001).  Other studies have explored crosslinking between transmembrane helices in 
engineered and wild type helical bundle proteins, such as keratin, cyclic nucleotide-gated 
channels and aspartate receptors (Chervitz and Falke, 1995; Fraser et al., 1988; Matulef 
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and Zagotta, 2002; Regan et al., 1994).  Disulfide crosslinking between adjacent alpha 
helices occurs when the residues are on opposing faces of the helices (Lee et al., 1995; 
Soskine et al., 2002) and have Cα-Cα distances less than 10 Å (Yang et al., 1996). 
 In the present study, we tested for crosslinking between cysteines introduced at 
two glycine receptor positions (S267 and A288) known to be involved with alcohol and 
inhaled anesthetic action.  The S267C/A288C double mutant had different characteristics 
from the wild type (WT) receptor.  Its current decreased with repeated applications of 
glycine, and it displayed tonic activity in the absence of neurotransmitter.  These 
characteristics were eliminated with the application of the reducing agent dithiothreitol 
and regained after application of mercuric chloride.  Mercuric chloride is a crosslinking 
agent that reacts with vicinal pairs of cysteines to form an intermolecular mercury-linked 
dimer, even in transmembrane regions with a low dielectric environment (Soskine et al., 
2002). 
Our results indicate that a disulfide bond had formed between these two 
introduced cysteine residues to crosslink transmembrane segments two and three. This is 
strong evidence that S267 and A288 are near-neighbors in the tertiary glycine receptor 
structure and that these amino acids both could contribute to a binding pocket for 
alcohols and volatile anesthetics.  Some of this work has been presented previously in 





3.2.1 Effect of Reduction on Glycine Currents in Wild Type and Mutant GlyRs 
In wild type glycine receptors, repeated exposures to 1 mM glycine elicited 
similar currents over time, and a three minute application of 1 mM DTT produced no 
significant change in the receptor function (Figure 7A and 7B).  Unlike the wild type, 
exposure to glycine (1 mM) caused a run-down of the glycine response in the 
S267C/A288C mutant.  This run-down was observed for 30 minutes after the first glycine 
application.  Following application of 1 mM DTT, the response of S267C/A288C to 
glycine recovered significantly (Figure 7C and 7D).  The single mutants, S267C and 
A288C were tested as controls and displayed responses similar to the wild type (Figure 
7E and 7F).  Oocytes co-injected with a 1:1 ratio of S267C + A288C did not show a 
current run-down and were similar to the wild type, indicating that intersubunit 




Figure  7. Reduction with dithiothreitol has no effect on wild type, S267C and 
A288C glycine receptors, but increases the response of S267C/A288C receptors to 
subsequent applications of glycine.  Glycine (1 mM, 20 s) was applied (at 15 minute 
intervals) three times before and three times after a three minute application of DTT (1 
mM) to oocytes expressing wild type or mutant glycine receptors.  A) A tracing of a 
single wild type response shows no change in current after reduction.  Oocytes were 
unclamped during DTT treatments, so this portion of the tracing is not shown.  B) Mean 
currents in the wild type receptor show no change with repeated applications of glycine 
and no change after reduction.    C) A tracing of a single oocyte expressing 
S267C/A288C shows that exposure to 1 mM glycine resulted in decrease in subsequent 
glycine responses, and that DTT reduction causes an increase in the glycine response.  D) 
The mean currents in the S267C/A288C receptor show the decreasing current elicited by 
glycine before reduction, and recovery of current after reduction.  E) and F) Mean 
currents in the S267C and A288C single mutants also show no change in current with 
repeated applications of glycine and no change after application of DTT.  Mean values ± 
SEM are shown for n = 5-13 oocytes per condition from 2-5 batches of oocytes.  *, p < 
0.05, ***, p < 0.001 as compared to final glycine response pre-reduction by one-way 
analysis of variance followed by Dunnett’s post test. 
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3.2.2 Effect of Reduction on GlyR α1(S267C/A288C) Leak Current, Tonic Activity 
and Baseline Current 
Immediately after clamping, a large, inward leak current, sensitive to strychnine, 
was apparent in the majority of GlyR α1(S267C/A288C)-expressing oocytes tested.  This 
current, never seen in the wild type receptor, declined immediately from the time of 
clamping to reach a stable baseline within 5-15 minutes.  When a stable baseline was 
reached, all experiments were performed.  Wild type glycine receptors do not respond to 
the channel antagonist strychnine in the absence of glycine.  The S267C/A288C mutant; 
however, displayed a tonic current after reaching a stable baseline that was reduced by 
strychnine, which closed the open channels.  This resulted in a decrease of the tonic 
inward current, suggesting that some channels were open in the absence of glycine 
(Figure 8A).  The strychnine effect on S267C/A288C receptors did not depend on prior 
activation with glycine.  After reduction with 1 mM DTT, strychnine no longer had a 
significant effect on the mutant receptors (Figure 8A and 8B).  After reduction, there was 
no leak current observed upon clamping.  Also, the baseline shifted, indicating that the 
spontaneous inward leakage current was reduced in the mutant receptor and that the 
mutant channels had closed.  This shift in baseline was significantly different from the 




Figure 8. Effects of reduction on S267C/A288C tonic activity and baseline shift 
following reduction.  A) Unlike wild type receptors that do not respond to applications 
of strychnine, S267C/A288C receptors close with a 10 µM strychnine application (40 s).  
The strychnine response occurred both without prior activation with glycine or after 
activation with glycine (as shown above).  After reduction with DTT (1 mM, 3 min), 
strychnine no longer had an effect.  B) The mean decrease in the tonic inward current of 
S267C/A288C receptors by 10 µM strychnine before and after reduction (n = 9 oocytes 
per condition from 3 batches of oocytes).  **, p < 0.01 as compared to the effect before 
reduction by the Student’s t test.  C) The baseline current shifted after reduction in the 
S267C/A288C mutant and appeared as a decrease in inward current.  The change in 
baseline of the wild type was compared to S267C/A288C.  Mean values ± SEM are 
shown for n = 14 wild type oocytes from 5 batches of oocytes, and from n = 34 mutants 
from 16 batches of oocytes.  ***, p < 0.001 as compared to the wild type using the 
Student’s t-test. 
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3.2.3 Effects of Reduction and Crosslinking on Wild Type, S267C, A288C and 
S267C/A288C Glycine Receptors 
We also asked if the mutant receptor could be cycled between its aberrant and 
wild type characteristics by reduction with DTT, followed by re-crosslinking with HgCl2 
(Soskine et al., 2002) and then a second application of DTT.  This experiment tested the 
reversibility of covalent bond formation between these two amino acids in the mutant 
receptor.  In the wild type receptors there was no significant change in current (elicited by 
1 mM glycine) after applications of either DTT or HgCl2 (Figure 9A and 9C).  For either 
S267C or A288C, there was no significant change in mean current after applications of 
either DTT or HgCl2, though both showed variable responses like the WT (some oocytes 
showed a decrease or an increase in current, while others showed no change) after the 
HgCl2 applications (Figure 9C).  The current of the S267C/A288C mutant receptor was 
altered significantly after applications of DTT or HgCl2, with DTT causing a significant 
increase in the receptors’ response and HgCl2, causing a significant decrease in receptor 
function.  These functional changes were measured 15 minutes after the DTT or HgCl2 
applications (Figure 9B and 9C). 
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Figure 9.  Effects of reduction and crosslinking on WT, A288C, S267C and 
S267C/A288C glycine receptors currents.  Two applications of glycine (1 mM, 20 s) 
were applied at 15 minute intervals, followed by reduction with DTT (10 mM , 3 min.), 
glycine (1 mM), crosslinking with HgCl2 (10 µM, 1 min.), glycine (1 mM), a second 
reduction step with DTT (10 mM , 3 min.), and a final test with glycine (1 mM).  A) This 
tracing of the glycine response in the WT receptor shows that the current does not change 
significantly after reduction and crosslinking.  B) A tracing from the S267C/A288C 
mutant shows that reduction increases the glycine response, mercuric chloride nearly 
eliminates the current induced by 1 mM glycine, and that a subsequent reduction step 
again increases the glycine response.  C) The normalized mean currents ± SEM are 
shown for the WT, A288C, S267C and S267C/A288C receptors.  Currents were 
normalized to 1.0 by dividing the currents of the wild type and mutant receptors by the 
current induced by the initial glycine application.  The data represents mean currents 
from n = 5-6 oocytes per condition from 2-4 batches of oocytes.  One-way analysis of 
variance followed by the Dunnett’s post test was used to determine differences in the 





3.2.4 Effects of Alcohols and Volatile Anesthetics on Wild Type and Mutant Glycine 
Receptors 
The effects of two alcohols (ethanol and octanol) and two volatile anesthetics 
(isoflurane and chloroform) were tested on the wild type, S267C, A288C, and 
S267C/A288C receptors.  The EC5-10 of glycine was determined for each oocyte.  
Responses were tested after a one minute pre-incubation of the drug, using the EC5-10 
glycine.  The single S267C mutation reduced or eliminated all drug responses tested 
except that of isoflurane.  Meanwhile, the A288C mutation reduced or eliminated all drug 
responses tested except chloroform.  The double mutant, S267C/A288C, reduced or 
eliminated the responses of all four drugs in comparison to the wild type receptors.  The 
mean responses of the wild type and mutant receptors to these four drugs and the average 
EC5-10 glycine values of the receptors are presented in Table 1. 
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Table 1 
Glycine EC5-10 and alcohol and volatile anesthetic responses of the WT glycine receptors 
and the cysteine substitution mutants. 
 
Glycine 
Receptor EC5-10 (µM) 
 
Percent Potentiation 
      
  Ethanol Octanol Isoflurane Chloroform 
      
WT 63 ± 4 80 ± 10 170 ± 20 450 ± 50 200 ± 30 
      
S267C 43 ± 6 0 ± 6 ** 90 ± 30 * 520 ± 150 10 ± 10 ** 
      
A288C 230 ± 10 ** -10 ± 10 ** 30 ± 20 ** 150 ± 30 ** 190 ± 30 
      
S267C/A288C 95 ± 10 10 ± 4 ** 20 ± 7 ** 110 ± 20 ** 60 ± 10 ** 
      
 
Percent potentiation of EC5-10 glycine responses to ethanol (100 mM), octanol (115 µM), 
isoflurane (0.77 mM) and chloroform (2.0 mM) are expressed as a mean ± SEM of 4 to 
28 oocytes per condition from 2-17 batches of oocytes.  S267C/A288C receptors were 
tested for their responses here after application of maximal glycine and EC5-10 glycine 
determination in the uniform crosslinked state.  * p<0.05, ** p<0.01; significantly 
different from wild type receptors by one-way ANOVA with Dunnett’s post test. 
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3.2.5 Effects of Volatile Anesthetics on S267C/A288C Glycine Receptors Before and 
After Reduction  
To determine whether reduction of the S267C/A288C receptors altered the drug 
responses, the drugs were tested approximately 45 minutes after application of 1 mM 
DTT while the receptors were in a uniformly reduced state.  After reduction, the EC5-10 
glycine was re-determined for each oocyte (average = 40 ± 15 µM), and the drugs were 
tested.  The two alcohols still had no effect (data not shown), but the two anesthetics now 
potentiated the glycine response.  The response of the reduced mutant to isoflurane was 
significantly greater than the response of the crosslinked S267C/A288C receptors, but did 
not recover to the level seen in the wild type.  Additionally, the response of the reduced 
S267C/A288C receptors to chloroform was significantly larger than that of the 
crosslinked receptors and recovered to a response similar to that of the wild type 




Figure 10. Effects of volatile anesthetics on the wild type glycine receptor and drug 
effects on S267C/A288C before and after reduction.  A) Isoflurane (0.77 mM) and 
chloroform (2.0 mM) both potentiate the wild type (black bars) response to EC5-10 
glycine.  These effects are smaller in the crosslinked S267C/A288C mutant (white bars).  
After reduction with 1 mM DTT (3 min), the max glycine response and EC5-10 glycine 
was re-determined to test the drugs a second time.  Post-reduction, both isoflurane and 
chloroform potentiated the glycine response to a greater extent than before (gray bars).  
Mean values ± SEM are shown for n = 4-7 oocytes per condition from at least 2 batches 
of oocytes.  **, p < 0.01, *** p < 0.001,  as compared to wild type potentiation and  #, p 
< 0.05 as compared to crosslinked receptor potentiation, Student’s t-test.  B) This 
example tracing of the S267C/A288C mutant shows the effect of chloroform on the EC5-
10 glycine response in the crosslinked and reduced states in a single oocyte. 
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3.2.6 Additional Double Cysteine Mutants 
Two additional double cysteine mutants were tested.  In both cases, the pairs of 
amino acids chosen to mutate were predicted by the homology model and/or evidenced 
by the substituted cysteine accessibility method to face the water-filled, drug-binding 
cavity at the center of the four transmembrane segments of each α1 subunit.  The pairs 
were either an alpha helical turn up or down from the S267/A288 pair.  GlyR 
α1(M263C/L291C) is a turn more cytoplasmic, and GlyR α1(S270C/I285C) is a turn 
toward the extracellular space.  Oocytes injected with S270C/I285C (n = 26) and 
M263C/L291C (n = 36) did not show any response to applications of 1 or 10 mM 
glycine.  Following application of DTT (1 mM or 10 mM), the S270C/I285C (n = 7) and 
M263C/L291C (n = 16) receptors still showed no response to glycine.  The GlyR 
α1(S270C/I285C) and GlyR α1(M263C/L291C) receptors tested were both unresponsive 
to glycine.  To speculate, these receptors may not have folded properly and were not 
expressed.  It is also possible that disulfide bonds may have formed, but they are 
stabilizing a non-functional form of the receptor.  However, this is unlikely because 
dithiothreitol did not restore function in either mutant.
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3.3 Discussion 
These results suggest that an intrasubunit disulfide bond forms between S267C 
and A288C in GlyR α1(S267C/A288C) receptors.  These two amino acids can covalently 
react with one another to link transmembrane segments two and three.  Disulfide bond 
formation can occur spontaneously, in the absence of additional oxidizing or crosslinking 
agents, to change the receptor’s characteristics.  Reduction of the disulfide bond with 
dithiothreitol largely restores receptor function to that of wild type.  Also, these cysteines 
can be crosslinked again with an application of mercuric chloride, which adds a 4 Å 
bridge between the two cysteines. 
 One possibility is that disulfide bonds may form between S267C and A288C 
during protein folding and processing in the oxidizing environment of the endoplasmic 
reticulum.  However, considering that one of the characteristics of this double mutant is a 
decrease in the current induced after an application of glycine, it seems likely that some 
disulfide bonds are forming during the process of channel gating.  Support for this 
hypothesis includes evidence that in the GABAA receptor the presence of GABA 
increases accessibility to amino acids in TM3, indicating movement of TM3 with channel 
gating (Williams and Akabas, 1999).  Also, in the glycine receptor, sulfhydryl-specific 
reagents react with the glycine receptor single cysteine substitution mutant A288C in the 
open state of the receptor, but not in the closed state (Harris et al., 2003; Lobo et al., 
2004a).  These results indicate that a conformational change occurs with channel gating 
to enlarge a water-filled, intrasubunit cavity and place residue 288 in the putative drug-
binding cavity facing S267 (Lobo et al., 2004a).  This movement could place S267C and 
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A288C in proximity to form a disulfide bond.  A recent abstract suggests a very low level 
of crosslinking using oxidizing agents between cysteines introduced into proximate 
positions (S270C/V292C) of the GABAA receptor (Bali and Akabas, 2003), which may 
generalize our findings in the glycine receptor to the rest of the ligand-gated ion channel 
family. 
 Intersubunit crosslinking has been demonstrated between TM2 segments in the 
GABA receptor (Horenstein et al., 2001).  To further test our hypothesis that S267C and 
A288C faced a common pocket within each subunit, rather than facing the interface and 
forming intersubunit crosslinks, we compared the behavior of S267C/A288C double 
mutants with oocytes co-injected with a 1:1 ratio of S267C + A288C cDNAs.  The co-
injected single mutant subunits behaved like the wild type rather than the S267C/A288C 
double mutant, indicating that intersubunit crosslinking was not occurring.  This supports 
our model that S267C and A288C face a common intrasubunit pocket. 
 Conformational analysis of disulfide bridges in high resolution crystal structures 
indicate the distance between the alpha carbons nearest to the sulfur atoms of covalently-
bound cysteines range from 4.6 to 7.4 Å (Thornton, 1981).  Analysis of 351 disulfide 
bridges showed the most common distance is approximately 5.6 Å with a Cα-Cβ-S (C-C-
S) bond angle of 114 degrees (Petersen et al., 1999).  From our molecular model of the 
glycine receptor transmembrane region, S267C and A288C are positioned at the interface 
between TM2 and TM3.  The residues are in close enough proximity to form a right-
handed disulfide bond with a distance and angle comparable to those above.  In this 
model, the distance between the alpha carbons of S267 and A288 is 7 Å and the C-C-S 
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bond angle is 112 degrees (Figure 11).  The two residues are nearer to one another than 










Figure 11. Model of the disulfide bond formed between S267C and A288C of the 
GlyR α1(S267C/A288C) receptor.   Our data indicates disulfide bond formation in the 
absence of oxidizing agents between introduced cysteines at positions S267 and A288.  
This molecular model of the glycine receptor transmembrane regions illustrates this 
disulfide bond.   The distance between the alpha carbons of S267 and A288 is 7 Å and 
the C-C-S bond angle is approximately 112 degrees. 
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Endogenous disulfide bonds necessary for glycine receptor function are located in 
the extracellular domain of the receptor (Rajendra et al., 1997; Rajendra et al., 1995).  
These disulfide bonds must be well protected because the concentrations of DTT used in 
our experiments did not alter the wild type glycine receptor function.  Others have also 
noted that exposure of wild type GlyRs and GABAA receptors to DTT had no significant 
effect on current magnitude following washout (Horenstein et al., 2001; Kash et al., 
2003; Lynch et al., 2001).  Also, there is an endogenous cysteine in TM3 (C290) of the 
wild type and mutant receptor subunits.  There may be a very low level of crosslinking 
between S267C and C290C because the S267C single mutant showed a non-significant 
trend in responses similar to S267C/A288C.  Overall, because the currents of S267C 
were statistically similar to wild type, C290 does not seem to be involved in crosslinking 
with the cysteine introduced in TM2 and other free cysteines in the wild type to any 
significant extent. 
 Interestingly, all four of the alcohols and anesthetics tested had eliminated or 
reduced effects in the S267C/A288C mutant.  The simplest explanation for the alcohol 
data is that alcohol potentiation for the glycine receptor is abolished by the cysteine 
substitutions independent of formation of disulfide bonds.  It is not surprising that 
reduction cannot restore the wild type effects of alcohols in the double mutant, since the 
single mutant S267C does not respond to ethanol, and A288C responds to neither ethanol 
nor octanol.  In contrast, after reduction with dithiothreitol, the two volatile anesthetics 
tested were able to potentiate the S267C/A288C receptors.  Isoflurane and chloroform 
both cause smaller potentiations than the wild type receptors when the S267C/A288C 
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receptors are crosslinked.  After reduction, the chloroform potentiation of S267C/A288C 
recovered to be similar to WT and the potentiation by isoflurane increased.  From these 
data, it is clear that the disulfide bond is interfering with allosteric modulation by 
anesthetic drugs on this region of the receptor.  One possibility is that reduction of the 
disulfide bond removes this obstruction from the binding site and increases the volume of 
the drug-binding cavity to allow the anesthetics to stably bind and cause receptor 
potentiation. 
Natural disulfides serve to stabilize protein structure by decreasing the degrees of 
freedom of movement (or entropy) of the unfolded state, forcing the equilibrium to the 
folded state (Wetzel, 1987).  Likewise, introduced disulfide bridges have been shown to 
result in increased stability of mutant proteins (Matsumura et al., 1989).  In the case of 
the S267C/A288C mutant, crosslinking the transmembrane segments to one another 
results in a functioning protein with an unnaturally limited flexibility.  In particular, the 
region of TM2 where S267 is located has been demonstrated to have high flexibility in 
nuclear magnetic resonance experiments with TM2 peptides (Yushmanov et al., 2003).  
Because this region plays a role in conducting the signal of agonist binding to the TM2-3 
linker and into TM2 (Kash et al., 2003), it makes sense that our introduced disulfide bond 
produces changes in channel function. 
Restriction of the dynamic movement of TM2 by covalently linking it to TM3 
changes channel properties.  Wild type glycine receptors exist in multiple receptor states:  
the unliganded closed state, and many liganded open and desensitized states.  The normal 
dynamics between these receptor states are disturbed by the double bond between S267C 
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and A288C, and this is noticeable at the whole cell level.  As the population of 
S267C/A288C mutant channels open with the first application of glycine, they take much 
longer to close than the wild type receptors, indicating the difficulty in moving from one 
channel conformation to another.  Additionally, further applications of glycine produce 
minimal glycine responses in the mutant receptors, indicating that they may be 
preferentially stabilized in the desensitized state or "frozen" in the resting state, where 
they are not responsive to glycine.  These characteristics are eliminated with reduction, 
which shows that once the restrictive disulfide bonds are broken, the channels can behave 
in a more similar manner to the wild type channels. 
These data demonstrate the orientation and near-neighbor proximity of S267 and 
A288 because of the ability of these two amino acids to form a disulfide bond.  These 
data locate the vertical position of TM2 with respect to TM3 and shows that they face one 
another.  Most importantly, disulfide bonding between these two introduced cysteines 
provides insight regarding the location and role of the TM2-TM3 interface. 
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4.0 Transmembrane Segment 1 
 
A portion of this chapter (4.2.2) was published in an article in The Journal of Biological 
Chemistry in August 2004 and is reprinted with permission. ©2004 Journal of Biological 
Chemistry, American Society for Biochemistry and Molecular Biology, Inc., Bethesda, 
MD, 20814. 
 
Lobo IA, Mascia MP, Trudell JR, Harris RA. Channel gating of the glycine receptor 
changes accessibility to residues implicated in receptor potentiation by alcohols and 
anesthetics. J Biol Chem. 2004 Aug 6;279(32):33919-27. Epub 2004 May 28. 
 
 
4.1 Introduction to Transmembrane Segment 1  
The secondary structure of transmembrane segment 1 has been the most difficult 
to ascertain of the four transmembrane segments.  Though it has been known that TM1 is 
a hydrophobic segment with a length of 20 amino acids, the structure has been 
controversial.  Evidence has suggested it is an alpha helix, beta sheet, and a mixture 
between the two. 
Results using the substituted-cysteine accessibility method in the acetylcholine 
receptor had an irregular pattern of exposure that did not correspond to either an alpha 
helix or a beta sheet (Akabas and Karlin, 1995).   TM1 showed accessibility in the most 
 64
extracellular portion and this region of TM1, with TM2, was hypothesized to contribute 
to the channel pore (Akabas and Karlin, 1995).  Likewise, the pattern of labeling with 
several with lipophilic photoactivable reagents showed that labeled amino acids had an 
irregular pattern, and this pattern was also inconsistent with either an alpha helix or a beta 
sheet (Barrantes, 2003; Blanton and Cohen, 1994).  Researchers, have for these reasons, 
interpreted TM1 as having a substantial amount of non-helical structure in addition to 
kinks from an evolutionarily conserved proline, present in all members of the LGIC 
family (Barrantes et al., 2000).  More recently, using different hydrophobic, 
photoreactive probes, Blanton et al. found the structure of TM1 was still not definitive, 
but could be a distorted alpha helix or beta sheet (Blanton et al., 1998b).  In experiments 
using limited proteolysis of the glycine receptor coupled with mass spectrometry, 
cleavage sites were noted in TM1 (Leite et al., 2000).  The authors suggested these short 
fragments were more consistent with a beta sheet structure (Leite et al., 2000; Leite and 
Cascio, 2001).   
The 4 Å nicotinic acetylcholine receptor cryo-electron microscopy structure 
provided perhaps the best data to date to define the secondary structure of TM1 
(Miyazawa et al., 2003).  Here, TM1 was shown to be an alpha helix, and part of a 
“classical” four-alpha-helical bundle.  TM1, TM3 and TM4 formed an outer ring of 
fifteen helices surrounding, but separated by water from, the TM2 inner ring of helices 
(Miyazawa et al., 2003).  Additionally, a consensus of 10 secondary structure prediction 
methods has indicated that TM1 and the other three TM segments are all alpha helical 
segments (Bertaccini and Trudell, 2002). 
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In terms of contributing to an alcohol and volatile anesthetic binding site, one 
position in TM1, I229C, has been implicated as important for volatile anesthetic action.  
It is, to date, the least characterized of the three known positions critical for 
alcohol/anesthetic action (I229, S267 and A288).  The first evidence that I229 was 
important for anesthetic action was published by Greenblatt and Meng, who tested a 
number of TM1 single mutants that converted the original amino acid to the 
corresponding GABA rho amino acid (Greenblatt and Meng, 1999).  They tested the 
effect of halothane on these mutants, and found that the I229F mutant was not potentiated 
by halothane.  The second reference that mentions this position is by Jenkins et al. who 
studied the homologous site in the GABAA receptor, L232 (Jenkins et al., 2001).  They 
found the L232F mutant was insensitive to halothane, but still sensitive to isoflurane, and 
found that introducing a larger amino acid L232W caused the receptor to be insensitive to 
both halothane and isoflurane. 
As it is known that there are some conformational changes occurring with channel 
gating in TM1 of the acetylcholine receptor (Akabas and Karlin, 1995; Zhang and Karlin, 
1997), we tested whether neurotransmitter binding changed accessibility to this specific 
position in the glycine receptor using the substituted-cysteine accessibility method 
(Karlin and Akabas, 1998).  Since I229 has been implicated to be critical for alcohol and 
anesthetic action, it is an attractive target for mutagenesis and probing with MTS 
reagents.  Here, site-directed mutagenesis was used to substitute a cysteine for the native 
isoleucine to make an I229C mutant.  The I229C receptor was probed using MTS 
reagents of two lengths.  Propyl MTS and decyl MTS were tested for reaction at the 
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introduced cysteine in the presence and absence of glycine.  Then, the effects of ethanol, 
octanol, isoflurane and chloroform were tested on the mutant and compared to the WT.  
Additionally, using an experimental strategy used previously for S267C (Mascia et al., 
2000), the ability of propyl MTS to block further potentiation of I229C by volatile 




4.2.1 I229C Concentration Response Curve Data 
The I229C mutant was tested for its response to glycine in a concentration 
response curve.  The glycine EC50 values and the Hill slopes for this mutant were 
compared to the wild type receptor.  The I229C was significantly more sensitive to the 




Glycine EC50 and Hill coefficients for the wild type (WT) receptor and I229C mutant.  
The average glycine EC50 and Hill coefficients were experimentally calculated from fits 
of concentration response curves from single oocytes and are expressed as a mean ± S.E. 
of 6 to 7 oocytes. 
 
Glycine Receptor EC50 (µM) Hill Coefficient 
   
WT 280 ± 47 2.3 ± 0.56 
   
I229C 110 ± 7** 3.5 ± 0.48 
   
 
** p < 0.01; significantly different from WT receptor by the unpaired Student’s t-test.
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4.2.2 Effects of MTS Reagents on I229C 
Accessibility of MTS reagents to I229 were tested in both the presence and 
absence of glycine.  For I229C, propyl MTS (500 µM) resulted in significant 
enhancement after application in the presence of glycine, but caused no change after 
application in the absence of glycine.  Likewise, decyl MTS (50 µM) showed labeling in 
the presence, but not in the absence of glycine (Figure 12).   
These same MTS concentrations were tested for their effects on WT receptors.  
Control propyl MTS applications (500 µM) on the WT did not produce an irreversible 
change in current after application in the absence (100 ± 6 % of control, n = 4) or in the 
presence (110 ± 4 % of control, n = 4) of 1 mM glycine.  Control applications of decyl 
MTS (50 µM) also did not change the WT receptor function in the absence (86 ± 10 % of 





Figure 12.  Covalent reaction of GlyR α1 mutant I229C with propyl and decyl MTS.  
Propyl MTS (500 µM) and decyl MTS (50 µM) reacted and resulted in enhancement of 
receptor function only after application in the presence of 1 mM glycine.  Data are 
expressed as a mean ± S.E. of 5 to 7 oocytes.  The paired Student’s t-test was used to 
determine significance of differences in the glycine EC5-10 before (control) and after 
treatment of MTS (* p < 0.05 and ** p < 0.01). 
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4.2.3 I229C Responses to Alcohols and Volatile Anesthetics 
The responses of the I229C mutant to alcohols and anesthetic molecules was 
determined and compared to the WT receptor.  Percent of control effects of ethanol (100 
mM), octanol (115 µM), isoflurane (0.8 mM) and chloroform (2.0 mM) were tested on an 
EC5-10 concentration of glycine, which was determined for each oocyte.   
The drug response profile of I229C was altered due to the substitution when 
compared to the WT responses.  The two alcohols tested (ethanol and octanol) had no 
potentiating effect as seen in the WT receptor.  The response to isoflurane was decreased 
significantly, while the response to chloroform was unchanged (Table 3). 
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Table 3 
Responses of WT and I229C receptors to ethanol (100 mM), octanol (115 µM), 
isoflurane (0.8 mM) and chloroform (2.0 mM).  Percent of control responses were 
measured on the EC5-10 glycine responses (determined for each oocyte). 
 
Glycine Receptor Glycine Response (Percent of Control) 
     
 Ethanol Octanol Isoflurane Chloroform 
     
WT 180 ± 11 270 ± 17 820 ± 82 300 ± 35 
     
I229C 89 ± 8 *** 110 ± 8 *** 220 ± 21 *** 240 ± 58 
     
 
 
Data are expressed as a percent of control of the mean ± S.E. of 4 to 18 oocytes.  
Mutant responses were compared to the WT with the unpaired Student’s t-test (** p < 






4.2.4 Effects of Volatile Anesthetics on I229C Before and After Reaction with Propyl 
MTS 
Since I229C reacts with MTS and is a water-accessible position, one can ask if 
the binding of MTS reagents at these positions could block further potentiation of the 
glycine receptor response by alcohols and anesthetics.  This experimental procedure was 
previously used to test whether S267C was involved with drug binding or was an 
allosteric site affected by drugs (Mascia et al., 2000).  Since MTS reaction blocked 
further drug effects at S267C, this indicated that the MTS reagents were permanently 
occupying the drug binding cavity and thereby preventing a other drug molecule from 
binding to and effecting the receptor. 
The effects of isoflurane (0.8 mM) and chloroform (2.0 mM) were tested on the 
EC5-10 glycine response of I229C.  Propyl MTS was applied in the presence of 1 mM 
glycine for reaction with receptors, and the maximal glycine response and EC5-10 glycine 
concentration was re-determined.  Then the ability of propyl MTS (500 µM) to alter the 
responses of these two volatile anesthetics was determined.  Application of propyl MTS 







Figure 13. Effects of volatile anesthetics on I229C before and after application of 
propyl MTS in the presence of 1 mM glycine.  The potentiation of the glycine EC5-10 
current by isoflurane (iso; 0.8 mM) and chloroform (chl; 2.0 mM) was measured before 
and after the application of 500 µM propyl MTS (applied in the presence of 1 mM 
glycine).  Propyl MTS application produced no change in the responses of isoflurane and 
chloroform.  Data are expressed as a mean ± SEM of 3 to 8 oocytes.  The unpaired 
Student’s t-test was used to determine differences in the percent of control responses of 





MTS reagents only reacted with I229C in the presence of glycine.  Both propyl 
and decyl MTS showed state-dependent reaction, indicating a change in receptor 
conformation with channel gating allows I229C to react.  This is an interesting finding 
since the major conformational changes due to channel gating occurring in the 
transmembrane domain of the receptor are usually considered to involve mainly the TM2 
segment.   
  In comparing our results in the glycine receptor (Lobo et al., 2004a) with 
published data on TM1, there is little consistency in accessibility between the different 
subunits that have been examined (Table 4).  The sequences were aligned using the 
consensus sequences of the ligand-gated ion channels by Bertaccini and Trudell 
(Bertaccini and Trudell, 2002).  The only complete data sets on TM1 segments are from 
the mouse acetylcholine alpha subunit (Akabas and Karlin, 1995) and the mouse 
acetylcholine beta subunit (Zhang and Karlin, 1997).  There have been no complete 
SCAM studies on any inhibitory ligand-gated ion channels to data.  While I229C is 
reactive only in the presence of glycine, the aligned residue in the alpha subunit of the 
AChR (I220) is accessible only in the absence of neurotransmitter.  Additionally, I220C 
reacts with the sulfhydryl-specific compound MTSEA, but does not react under either 
condition with MTSES.  Meanwhile, in the AChR beta subunit, the aligned residue A231 
is not reactive in the absence or presence of neurotransmitter with either MTSEA or 
MTSES.  It seems that the positioning of this residue is quite variable between different 
subunits, which leads to these variable reactivity results (Table 4).
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Table 4 
TM 1 reactivity summary.  Our reactivity data for I229C of the glycine receptor (Lobo et 
al., 2004a) is shown with other SCAM data published on TM1 from the acetylcholine 
receptor (Akabas and Karlin, 1995; Zhang and Karlin, 1997).  The receptor subunit and 
sulfhydryl-specific reagents used in the experiments are indicated.  The glycine receptor 
results were determined using an EC5-10 test pulse of glycine.  Akabas and Karlin and 
Zhang and Karlin both used a maximal test pulse of acetylcholine to determine changes 















































































































































































































































































































































































































































































In contrast to S267C (Mascia et al., 2000), while propyl MTS reaction occurred 
with I229C in the open state and caused an enhancement of receptor function, reaction 
with propyl MTS was unable to block further potentiation by the glycine receptor 
modulators isoflurane and chloroform.  Reasons for this may be that the introduced MTS 
reagent is not the correct size or shape to mimic a drug molecule, and therefore prevent 
isoflurane and chloroform action.  Testing a larger MTS reagent that would fill more of 
the putative drug binding cavity may resolve this question.  Another possibility is that 
this position is located in the alcohol and volatile anesthetic binding cavity, but it is not 
playing a direct role in binding isoflurane and chloroform.  However, since the I229C 
mutation eliminated the effect of ethanol and octanol and reduced the potentiation by 
isoflurane, the position does seem to be important for receptor potentiation by alcohols 
and anesthetics.  Also, in other studies, mutations at this position have indicated that this 
position is important for drug action (Greenblatt and Meng, 1999; Jenkins et al., 2001).  
Currently, the mechanism for this action is not fully clear.  Though, propyl MTS was 
unable to block potentiation by octanol and isoflurane, these two residues may play a role 
in stabilizing drug molecules in the binding cavity or allow a drug to be properly 
orientated to cause its effects.
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5.0 Transmembrane Segment 2 
 
Portions of this chapter were published as an article in The Journal of Biological 
Chemistry in August 2004 and are reprinted with permission. ©2004 Journal of 
Biological Chemistry, American Society for Biochemistry and Molecular Biology, Inc., 
Bethesda, MD, 20814. 
 
Lobo IA, Mascia MP, Trudell JR, Harris RA. Channel gating of the glycine receptor 
changes accessibility to residues implicated in receptor potentiation by alcohols and 
anesthetics. J Biol Chem. 2004 Aug 6;279(32):33919-27. Epub 2004 May 28. 
 
 
5.1 Introduction to Transmembrane 2 
An amino acid in TM2 (S267) of the glycine receptor is critical for the action of 
both alcohols and volatile anesthetics (Jenkins et al., 2001; Mihic et al., 1997; Ueno et al., 
2000; Wick et al., 1998; Yamakura et al., 2001; Ye et al., 1998b).  To study and identify 
water accessible residues of ion channels, such as those in drug binding pockets, 
methanethiosulfonate (MTS) reagents may be used as structural probes using the 
substituted cysteine accessibility method (Karlin and Akabas, 1998).  MTS reagents 
rapidly react to form disulfide bonds with cysteines in the presence of water, and an 
irreversible change in receptor function is taken as evidence of disulfide bond formation.  
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By use of this method, residues accessible in the presence and/or absence of 
neurotransmitter to sulfhydryl-specific reagents have been determined for TM2 in 
GABAA and acetylcholine receptors (Horenstein et al., 2001; Xu and Akabas, 1996; 
Zhang and Karlin, 1998) and the TM2-TM3 loop for GABAA receptors (Bera et al., 
2002).  Lynch et al. demonstrated conformational changes occurring in the TM2-TM3 
loop in the glycine receptor with gating (Lynch et al., 2001).  Additionally, Mascia et al. 
(2000) found that covalent reaction of propyl methanethiosulfonate with a cysteine 
introduced in the putative alcohol/anesthetic binding site (S267C) of the glycine receptor 
irreversibly enhanced receptor function and abolished further potentiation by alcohols 
and anesthetics (Mascia et al., 2000). 
Glycine receptors predominate in the spinal cord and brain stem and are present in 
the ventral tegmental area, a brain region of importance in the rewarding effects of 
alcohol (Betz, 1991; Eggers et al., 2000; Langosch, 1995; Legendre, 2001; Ye et al., 
2001a).  Clinically relevant concentrations of ethanol, longer chain alcohols and volatile 
anesthetics enhance the function of the glycine receptor (and the homologous GABAA 
receptor) in heterologous expression systems (Krasowski et al., 1998; Mascia et al., 
1996a; Mascia et al., 1996b).  Numerous studies have shown ethanol potentiation of 
glycine activated currents in cultured cells, including neurons of the hippocampus and 
ventral tegmental area, brain synaptoneurosomes, and mouse and chick spinal cord 
neurons (Aguayo and Pancetti, 1994; Aguayo et al., 1996; Celentano et al., 1988; Eggers 
et al., 2000; Engblom and Akerman, 1991; Ye et al., 2001a).  As mediators of inhibition 
in the nervous system, glycine receptors may be involved in the sedative and anesthetic 
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effects of alcohol, a hypothesis supported by a recent study showing decreased alcohol 
effects in transgenic mice expressing a mutant, alcohol resistant, α1 subunit (Findlay et 
al., 2002).  The glycine receptor is one of the most credible candidates for mediating 
immobility caused by volatile anesthetics (Sonner et al., 2003). 
  These studies raise the question of the mechanism by which occupation of this 
protein cavity by alcohols, anesthetics or MTS reagents facilitates activation (or prevents 
inactivation) of the channel.  It is established that channel gating causes tertiary structural 
rearrangements within receptor subunits (Spencer and Rees, 2002), so we were interested 
in how channel gating causes changes in accessibility to the alcohol and anesthetic 
binding pocket.  We propose that the volume of this cavity, bounded by amino acids in 
TM1, TM2, and TM3, is larger in the open state of the channel than in the closed state.  
This would provide a mechanism by which occupation of the cavity by diverse small 
molecules can change receptor function.  Our experiments expand on previous work 
(Bera et al., 2002; Horenstein et al., 2001; Lynch et al., 2001; Mascia et al., 2000; 
Williams and Akabas, 1999; Williams and Akabas, 2000; Williams and Akabas, 2001; 
Williams and Akabas, 2002; Xu and Akabas, 1996; Zhang and Karlin, 1998) to use alkyl 
MTS compounds of different lengths as molecular instruments to estimate the volume of 
the drug-binding pocket.  In order to map the shape and organization of this binding 
cavity, we introduced cysteines at seven positions in TM2.  We studied the ability of 
MTS reagents of different lengths to covalently react with these seven positions in both 




5.2.1 MTS Reactivity at S267C and WT Controls 
We first tested the ability of MTS reagents of different lengths to covalently react 
with a cysteine introduced at amino acid residue 267 (S267C).  Propyl MTS irreversibly 
potentiated the glycine response after being applied in both the absence of glycine 
(Figure 14A) and in the presence of 1 mM glycine (Figure 14B).  In contrast, decyl MTS 
failed to irreversibly potentiate the S267C response following application in the absence 
of glycine (Figure 14C), but could react and irreversibly enhance S267C when applied in 
the presence of glycine (Figure 14D).   
We extended these observations by testing a series of MTS compounds of 
different sizes ranging from C1 (methyl) to C16 (hexadecyl) to determine their ability to 
react with S267C.  These neutral MTS reagents have structural similarities to alcohols 
and anesthetics.  Exposure to MTS reagents was carried out in the absence of glycine 
(closed state) and in the presence of a maximal concentration of glycine (1 mM, open and 
desensitized states).  Methyl MTS did not cause receptor enhancement after application 
in either the closed or the open state.  We found that MTS compounds of shorter chain 
lengths (propyl to octyl MTS) reacted with S267C when applied in both the presence and 
the absence of glycine, but the longer chain MTS compounds (decyl to hexadecyl MTS) 
were able to irreversibly react and alter the glycine response only when applied in the 
presence of glycine (Figure 14E).  In all cases, except hexyl MTS, the enhancement 
observed was greater after the MTS reagent was applied in the presence of glycine, but 
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Figure 14.  Effect of MTS reagents of different chain lengths on GlyR α1(S267C).  
A) and B) The glycine current resulting from an EC5-10 of glycine is enhanced 20 minutes 
after application of 50 µM propyl MTS in the absence and presence of glycine (1 mM).  
C) The glycine current is not enhanced significantly when 50 µM decyl MTS is applied 
in the absence of glycine.  D) Significant enhancement of receptor function occurs after 
50 µM decyl MTS is co-applied with 1 mM glycine.  E) MTS compounds (50 µM) with 
chain lengths ranging from propyl (C3) to hexadecyl (C16) were found to irreversibly 
enhance the receptor when co-applied in the presence of glycine (1 mM).  However, 
when applied in the absence of glycine, propyl through octyl (C8) MTS could cause a 
significant enhancement and longer MTS compounds had no effect on receptor function.  
Data are expressed as mean ± S.E. of 6-13 oocytes.  The paired Student’s t-test was used 
to determine significance of differences in the glycine EC5-10 responses before (control) 
and after treatment of MTS (* p < 0.05, ** p < 0.01, and *** p < 0.001). 
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In addition to the n-alkyl MTS compounds, we tested a sulfhydryl-specific 
reagent of a different shape as well as a charged reagent.  We observed that benzyl MTS 
and the negatively changed pCMBSֿ both caused enhancement of S267C after 
application in both conditions, but had no effect on the wild type (Table 5). 
Wild type receptors did not show an irreversible change in function following 
application of any of the MTS compounds at 50 µM (Table 5).  Also, the highest 
concentrations of propyl and decyl MTS used in our studies had no effect on wild type 
glycine receptor function.  Application of 1 mM propyl MTS (90 s) resulted in no 
significant change in current from control in either the absence (92 ± 9 % of control, n = 
4) or the presence (86 ± 5 % of control, n = 4) of 1 mM glycine.  Likewise, decyl MTS 
(300 µM, 90 s) resulted in no significant change in either the absence (91 ± 3 % of 
control, n = 4) or the presence (88 ± 9 % of control, n = 5) of 1 mM glycine. 
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Table 5 
Glycine responses, expressed as percent of control, of wild type and GlyR α1(S267C) 
receptors following application of sulfhydryl-specific reagents of different sizes. 
Glycine responses of receptors 20 minutes following a 50 µM application of MTS 
compounds or pCMBSֿ in either the absence of glycine or in the presence of 1 mM 
glycine.  Responses are expressed as percent of control initial EC5-10 responses before 
MTS application, and represent a mean ± S.E. of 4 to 13 oocytes. 
 
MTS Chain 
Length WT (No Gly) WT (1 mM Gly) S267C (No Gly) S267C (1 mM Gly) 
     
C1 100 ± 5 120 ± 9 160 ± 35 140 ± 22 
     
C3 110 ± 11 92 ± 11 390 ± 100* 970 ± 170*** 
     
C6 87 ± 9 110 ± 13 750 ± 200* 400 ± 110* 
     
C8 95 ± 5 88 ± 8 250 ± 39** 400 ± 120* 
     
C10 86 ± 10 83 ± 6 120 ± 21 520 ± 53*** 
     
C12 110 ± 5 92 ± 7 140 ± 24 580 ± 74** 
     
C16 88 ± 6 100 ± 7 86 ± 10 370 ± 85* 
     
Ring-Substituted:     
Benzyl MTS 73 ± 13 85 ± 6 2200 ± 670* 1700 ± 340** 
     
Charged:     
pCMBSֿ 82 ± 11 98 ± 12 500 ± 98** 510 ± 120* 
     
 




5.2.2 Testing for Silent Reaction of Long Chain MTS Compounds at S267C 
Of consideration was the possibility that although longer chain MTS compounds 
did not cause enhancement of the glycine response, they could be “silently” reacting with 
the receptor without altering receptor function.  In this way, the presence of MTS would 
go undetected.  This possibility was tested by exposing the receptor to 100 µM decyl 
MTS (a compound having no effect following application in the closed state) and 
measuring the glycine response, and following this with a subsequent application of 50 
µM propyl MTS (a compound that caused significant potentiation following application 
in the closed state) and measuring the glycine response in the same oocyte (Figure 15).  
Decyl MTS produced no change in the glycine response, and the subsequent application 
of propyl MTS produced a percent enhancement of 530 ± 160, a value not statistically 
different from the 390 ± 100 percent enhancement viewed following a single application 




Figure 15.  Decyl MTS does not block action of propyl MTS when applied in the 
closed state to GlyR α1(S267C).  To ensure that long chain MTS compounds were 
unable to label the cysteine in the closed state, labeling with 100 µM decyl MTS (no 
significant effect) was followed by a subsequent application of 50 µM propyl MTS 
(significant potentiation).  A) This is an example tracing of the glycine responses and B) 
shows the mean ± S.E. of the responses of 10 experiments.  The EC5-10 was determined 
for each oocyte (average = 48 ± 8 µM).  The paired Student’s t-test was used to 
determine significance of differences in the glycine EC5-10 responses before and after 
treatment of propyl and decyl MTS (* p < 0.05).  
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5.2.3 MTS Concentration Response Curves at S267C 
Various concentrations of propyl and decyl MTS were tested for reaction with 
S267C in the absence of glycine or in the presence of 1 mM glycine (Figure 16).  The 
time of MTS application was held constant at 90 s.  Propyl MTS caused enhancement 
after application in both the presence (30 µM and higher) and in the absence (50 µM and 
higher) of glycine.  Lower concentrations of propyl MTS (1, 10 and 30 µM) resulted in a 
small but significant inhibition when applied in the absence of 1 mM glycine.  The 
reaction reaches a maximum at 1 mM propyl MTS for both curves, with no statistical 
difference between the 500 µM and 1 mM points (Figure 16A).  Decyl MTS did not 
change glycine receptor function, irrespective of the concentration tested when applied in 
the absence of glycine.  When applied in the presence of glycine, concentrations of decyl 
MTS of 50 µM and greater resulted in enhancement, with the greatest percent 
potentiation after application of 100 µM decyl MTS.  The mean potentiation after 
application of 300 µM decyl MTS was not significantly different from that produced by 




Figure 16. Concentration response curves for propyl and decyl MTS in both the 
presence and absence of glycine for GlyR α1(S267C).  A) For propyl MTS, 
enhancement occurs when the propyl MTS is applied for 90 s in both the presence and in 
the absence of 1 mM glycine, increasing as the concentration is increased.  Lower 
concentrations of propyl MTS (1, 10 and 30 µM) resulted in a small but significant 
inhibition only when applied in the absence of glycine.  B) For decyl MTS, there was no 
change in glycine receptor function irrespective of the concentration applied (90 s) to the 
closed state of the receptor.  When decyl MTS was applied in the presence of glycine, 
concentrations of 50 µM and greater resulted in enhancement, with the greatest percent 
potentiation after application of 100 µM decyl MTS.  Arrows indicate the 50 µM 
concentration used in the earlier S267C experiments.  MTS reagents were applied for 90 
s, and glycine applications were 30 s.  Each concentration point represents 4-10 oocytes 
for the propyl MTS curve, and 4-11 oocytes for the decyl MTS curve.  Data are expressed 
as a mean ± S.E.  The paired Student’s t-test was used to determine significance of 
differences in the response to glycine EC5-10 before and 10 minutes after treatment of 
propyl or decyl MTS (* p < 0.05).
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5.2.4 Rates of Reaction with S267C 
We examined the state dependence of propyl, hexyl and decyl MTS reaction with 
S267C by measuring the rate of reaction in the presence and absence of glycine (Table 6).  
(For decyl MTS, no reaction occurred in the absence of glycine, and the rate of reaction 
was only measured with glycine).  The rate of reaction of propyl MTS in the presence of 
1 mM glycine (τ = 29 ± 6.5 s, k = 1050 ± 190 s-1M-1) was significantly faster than in the 
absence (τ = 138 ± 20 s, k = 169 ± 29 s-1M-1).  The rate of hexyl MTS reaction with 
S267C was also faster in the presence of glycine, and the reaction rates increased with 




Rates of reactions of propyl, hexyl and decyl MTS with S267C in the absence of glycine 
and in the presence of 1 mM glycine.  The steady-state rates of reaction of both propyl 
MTS and hexyl MTS increased significantly in the presence of glycine.  Additionally, 
reaction rates increased with increasing MTS chain length.  Rates are expressed as a 
mean ± S.E. of 3 to 12 oocytes. 
 
MTS Chain Length No Glycine (s-1M-1) 1 mM Glycine (s-1M-1)
   
Propyl MTS 169 ± 29 1050 ± 190 ** 
   
Hexyl MTS 629 ± 91 10700 ± 1400 ** 
   
Decyl MTS no reaction 70600 ± 7400 
  
** p < 0.01; significantly different from no glycine rate of reaction by Student’s t-test. 
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We also determined the rates of reaction of propyl MTS in both states in the 
presence of isoflurane, hypothesizing that the presence of an anesthetic could slow the 
reaction of MTS with S267C.  The presence of isoflurane (0.6 mM) did not change the 
rate of propyl MTS reaction significantly in the absence (τ = 124 ± 41 s, k = 220 ± 41  






Figure 17.  Rate of reaction of propyl MTS with S267C in four conditions.  A) An 
example tracing of the reaction of S267C with 50 µM propyl MTS is shown above.  The 
effect of these short exposures on the EC5-10 current of S267C was tested.  Each short 
exposure was 15 seconds long and the initial EC5-10 glycine (30 s) followed after 10 
minutes of washout.  This procedure was continued until the potentiation reached a stable 
plateau.  B) The rates of reaction of 50 µM propyl MTS with S267C were determined in 
four conditions:  1) in the absence of glycine, 2) 0.6 mM isoflurane in the absence of 
glycine, 3) in the presence of 1 mM glycine, 4)  0.6 mM isoflurane in the presence of 
glycine.  The currents were normalized and graphed for comparison and the pseudo-
second order rates were determined.  Reaction was significantly faster in the presence of 
glycine in both pairs of conditions.  Reactions were not altered significantly by the co-
application of 0.6 mM isoflurane. 
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5.2.5 Which S267C Receptor States are Reactive? 
One possible explanation of the MTS labeling results obtained in the presence of 
glycine is that MTS is covalently reacting with and stabilizing both the open and 
desensitized states of the receptor.  To differentiate between these two states, potentiation 
by isoflurane (0.8 mM) was tested following labeling S267C receptors (with 50 µM decyl 
MTS) in three states: closed (as a control), desensitized and open (Figure 18; see 
Materials and Methods).  The potentiation values for each condition were compared to 
the isoflurane potentiation of unlabeled receptors with the hypothesis that receptors that 
reacted with MTS would have eliminated or reduced isoflurane potentiation, as 
previously demonstrated (Mascia et al., 2000).  As expected, isoflurane potentiation 
following labeling in the closed state (Figure 18C) did not differ from that of unlabeled 
receptors (Figure 18B), further supporting the conclusion that decyl MTS is unable to 
react in the closed state.  MTS appears to react with and stabilize both the desensitized 
(Figure 18D) and open states (Figure 18E).  Following reaction of decyl MTS, isoflurane 
produced a current independent of glycine, as shown in the tracings, likely indicating that 
some channels were open in the absence of glycine. 
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Figure 18.  Isoflurane potentiation of the EC5-10 glycine response of S267C following 
labeling of the receptor in different states with 50 µM decyl MTS.  A) The 
potentiation of the EC5-10 glycine response by 0.8 mM isoflurane was measured on 
unlabeled receptors (B, No MTS) as the control.  Following application of 50 µM decyl 
MTS in the absence of glycine (closed) or in the presence of 1 mM glycine (open), the 
potentiation by isoflurane was measured.  Potentiation by isoflurane was also measured 
on receptors labeled in the “desensitized” state, where reaction with 50 µM decyl MTS 
followed application of 1 mM glycine for 11-14 minutes to desensitize receptors.  C) The 
closed state was not labeled by decyl MTS because there was no significant elimination 
in the isoflurane potentiation.  Both the desensitized and open states were labeled by 
decyl MTS, resulting in significant reduction of isoflurane potentiation.  In addition, 
isoflurane alone potentiated receptors after reaction with decyl MTS in the desensitized 
and open states indicating that these receptors now had tonic activity (D and E).  Data are 
expressed as a mean ± S.E. of 6 to 9 oocytes.  The average current elicited by EC5-10 of 
glycine before and after each isoflurane application was used to calculate the percent 
potentiation for each condition.  The mean average currents (nA) ± S.E. produced by an 
EC5-10 of glycine are as follows:  no MTS = 550 ± 100, closed = 400 ± 70, desensitized = 
330 ± 120, and open = 230 ± 50).  One-way ANOVA with the Dunnett’s post test was 
used to determine significance of differences in the isoflurane potentiated glycine EC5-10 
of the labeled receptors versus the control, “No MTS” isoflurane response in unlabeled 
receptors (*** p < 0.001). 
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5.2.6 Effect of Strychnine After Reaction of MTS with S267C 
It has been shown that MTS reaction at a position homologous to GlyR 
α1(S267C) in the 5-HT3 receptor (L293C) resulted in channels locked in the open state 
(Reeves et al., 2001).  We tested for this possibility by applying strychnine (10 µM) to 
S267C receptors following MTS labeling.  There was no effect of strychnine after propyl 
MTS (50 µM) was applied in either the open or the closed state (n = 4-6).  Predictably, 
there was also no effect of strychnine after application of 50 µM decyl MTS to the 
oocytes in the closed state (n = 5).  However, following decyl MTS (50 µM) reaction in 
the presence of 1 mM glycine, 10 µM strychnine blocked a small inward current of 110 ± 
34 nA (n = 7), indicating that some channels were constitutively open following labeling.  
In some cases, MTS reagents produced a current when applied in the absence of glycine 
on mutant receptors as seen in studies at this position in the GABA receptor with 
pCMBSֿ (Bali and Akabas, 2004).  The currents observed here were blocked by 10 µM 
strychnine indicating that MTS alone can open some channels.  In all cases, the currents 
produced by 50 µM MTS alone were very small (never exceeding 1 % of the maximal 
current), returned to baseline after the application and were never observed in the WT.  
Most often, we did not observe a current induced by MTS alone at all.  Because the MTS 
alone current is not appreciable, this should not change our interpretation of data for 




5.2.7 MTS Volumes After Reaction at S267C 
 The volumes of MTS reagents before and after reaction were calculated using 
Spartan 5.0 (Wavefunction, San Diego, CA).  The relevant volume for diffusion into the 
binding site is the whole molecular volume of the MTS reagent, whereas the relevant 
volume for functional analysis is the portion of the MTS molecule that reacts covalently 
with the substituted cysteine residue and causes the observed effects.  For each functional 
MTS volume that has covalently reacted given below, the sulfinic acid leaving group 
contributes approximately 65 Å3 to the MTS reagent volumes.  Propyl MTS (102 Å3) 
through octyl MTS (204 Å3) were able to covalently react with both open and closed 
states of S267C to produce enhancement of the glycine response.  Benzyl MTS, with a 
functional volume of 150 Å3, caused the largest responses after reaction in both states.  
Hexadecyl MTS (368 Å3) was the largest compound tested that could react in the 
presence of glycine to cause enhancement.  Substituting cysteine (123 Å3) in place of 
serine (110 Å3) resulted in a volume increase of 13 Å3. 
 
5.2.8  Glycine Concentration Response Curve Data for WT and TM2 Mutants 
Additionally six other neighboring residues in TM2 were mutated to cysteine and 
tested for accessibility to MTS reagents to determine the “ceiling” and “floor” of the 
binding cavity.  A recent nuclear magnetic resonance study of the TM2 segment (Tang et 
al., 2002), a consensus of ten secondary structure prediction algorithms for ligand gated-
ion channels (Bertaccini and Trudell, 2002) and the cryo-electron micrograph structure of 
the acetylcholine receptor (Miyazawa et al., 2003) all provide evidence that TM2 is an 
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alpha helix.  We selected the amino acids in TM2 that would be in close proximity to 
S267 in an alpha helix.  The residues targeted by mutagenesis were M263, T264, V260, 
T259 and G256 (helical turns toward the cytoplasm from S267) and S270 (approximately 
a helical turn up toward the extracellular surface).  The glycine EC50 values and the Hill 
slopes for these mutants were compared to the wild type receptor (Table 7).  The EC50 
values for T259C and A288C increased significantly from that of the wild type receptor.  
We chose propyl and decyl MTS to characterize these eight mutant receptors because of 
the labeling distinction we observed on S267C (Figure 14). 
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Table 7 
Amino acid positions (Miller, 1989), glycine EC50 and Hill coefficients for the wild type 
(WT) receptor and the cysteine substitution mutants studied.  The glycine EC50 and Hill 
coefficients were experimentally calculated from concentration response curves and are 
expressed as a mean ± S.E. of 4 to 10 oocytes. 
 
Glycine Receptor TM2 Position EC50 (µM) Hill Coefficient 
    
WT n/a 280 ± 47 2.3 ± 0.56 
    
S270C 18' 370 ± 90 1.3 ± 0.18 
    
S267C 15' 330 ± 56 1.1 ± 0.11 
    
T264C 12' 69 ± 32 3.5 ± 2.4 
    
M263C 11' 270 ± 80 3.0 ± 1.3 
    
V260C 8' 41 ± 24 2.8 ± 1.1 
    
T259C 7' 770 ± 110 ** 1.8 ± 0.31 
    
G256C 4' 670 ± 97 ** 1.3 ± 0.11 
    
 
** p < 0.01; significantly different from wild type receptors by one-way ANOVA with 
the Dunnett’s post test.
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5.2.9 Reaction of M263C and S270C with MTS Reagents 
For M263C, propyl MTS (500 µM) enhanced receptor function when applied in 
both the presence and the absence of glycine.  Decyl MTS (50 µM) caused no 
enhancement of M263C in either condition (Figure 19A).  For S270C, reaction with 
propyl MTS (500 µM) caused an irreversible change in receptor function when applied in 
both the presence and the absence of glycine.  Decyl MTS (50 µM) was able to enhance 




Figure 19.  Labeling of GlyR α1 mutants M263C and S270C with propyl and decyl 
MTS.  A) GlyR α1(M263C):  Propyl MTS (500 µM) resulted in significant enhancement 
when applied in both the absence and presence of glycine (1 mM).  Decyl MTS (50 µM) 
produced no change in receptor function in either condition.  B) GlyR α1(S270C):  
Propyl MTS (500 µM) resulted in significant enhancement when the MTS was applied in 
both the absence and the presence of glycine (1 mM).  Decyl MTS (50 µM) only caused 
enhancement after being co-applied with 1 mM glycine.  Data are expressed as a mean ± 
S.E. of 4 to 8 oocytes.  The paired Student’s t-test was used to determine significance of 
differences in the glycine EC5-10 before and after treatment of MTS (* p < 0.05). 
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5.2.10 Responses of WT, M263C and S270C to Ethanol, Octanol and Isoflurane 
For these two accessible mutants (M263C and S270C), the drug responses of 
ethanol, isoflurane and octanol were tested and compared to the WT receptor responses.  
The percent of control effects of ethanol (100 mM), by isoflurane (0.8 mM) and octanol 
(115 µM) were tested on an EC5-10 concentration of glycine, which was determined for 
each oocyte.  The enhancing effect of ethanol seen in the WT was abolished by 
introducing the cysteine mutations at M263C and S270C.  The effect of octanol was 
significantly reduced in both M263C and S270C.  The potentiation by isoflurane was 
increased significantly by the S270C substitution (Table 8).
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Table 8 
Responses of WT, M263C and S270C receptors to ethanol (100 mM), octanol (115 µM), 
and isoflurane (0.8 mM).  Percent of control responses were measured on the EC5-10 
glycine responses (determined for each oocyte). 
 
Glycine Receptor Percent of Control 
    
 Ethanol Octanol Isoflurane 
    
WT 180 ± 11 270 ± 17 820 ± 82 
    
M263C 110 ± 10 ** 160 ± 10 ** 520 ± 150 
    
S270C 120 ± 9 ** 200 ± 11 ** 2800 ± 530 ** 
    
 
 
Data are expressed as a percent of control of the mean ± S.E. of 8 to 18 oocytes from 4-6 
different frogs.  Mutant responses were compared to the WT with the one-way ANOVA 
and the Dunnett’s post-test (** p < 0.01).
 105
5.2.11 Response of WT, M263C and S270C GlyRs to Octanol and Isoflurane Before 
and After Reaction with Propyl MTS 
Since M263C and S270C are reactive sites, a question that follows from this data 
is to ask whether the binding of MTS reagents at these positions could block further 
potentiation of the glycine receptor response by alcohols and anesthetics.  This 
experimental procedure was used previously to test whether S267C was involved with 
drug binding or was an allosteric site affected by drugs (Mascia et al., 2000).  MTS was 
able to block drug effects at S267C, providing evidence that the MTS reagents were 
occupying the drug binding cavity and preventing a drug molecule from causing its 
effects on the receptor. 
The effects of octanol (115 µM) and isoflurane (0.8 mM) were tested on the WT, 
M263C and S270C receptors.  Then the ability of propyl MTS (500 µM) to alter the 
responses of these two drugs was determined.  Application of propyl MTS did not reduce 
or eliminate the alcohol or anesthetic potentiation of the WT or the M263C and S270C 




Figure 20. Effects of alcohols and anesthetics on GlyRα1 (WT), GlyRα1 (M263C) 
and GlyRα1 (S270C) before and after application of propyl MTS.  The potentiation 
of the glycine EC5-10 by isoflurane (0.8 mM) and octanol (115 µM) were measured before 
and after the application of 500 µM propyl MTS (in the presence of 1 mM glycine). A) 
Application of propyl MTS to the WT receptor produced no change in the response of the 
receptor to isoflurane and octanol.  B) Application of propyl MTS to the M263C receptor 
produced no change in the response of the receptor to isoflurane and octanol.  C) For 
S270C, propyl MTS application also produced no change in the response of the receptor 
to isoflurane and octanol.  Data are expressed as a mean ± SEM of 5 to 14 oocytes.  The 
paired t-test was used to determine differences in the average glycine EC5-10 response 
from before and after the drug application with the response during application of the 
drug (* p<0.05, ** p<0.01, and *** p<0.001). 
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5.2.12 Inaccessible Mutants in TM2 
No labeling was observed for the other four mutants (G256C, T259C, V260C and 
T264C) under any condition tested: 500 µM propyl MTS or 50 µM decyl MTS in either 




Percent of control responses to EC5-10 glycine following application of propyl or decyl 
MTS on wild type and TM2 mutant GlyRs in the presence or absence of glycine. 
TM2 mutants (T264C, V260C, T259C, G256C), in proximity to S267, were tested for 
accessibility to MTS reagents.  For the WT and T264C receptors, the maximal glycine 
concentration co-applied with propyl (500 µM) and decyl MTS (50 µM) was 1 mM, and 
for V260C, T259C and G256C, the maximal glycine concentration used was 10 mM.  
Data are expressed as a mean ± S.E. of 4 to 7 oocytes.  p > 0.05 for all receptor responses 













     
WT 100 ± 6.4 110 ± 4.5 86 ± 10 83 ± 6.0 
     
T264C 130 ± 33 85 ± 12 93 ± 24 139 ± 41 
     
V260C 98 ± 6.5 88 ± 11 110 ± 9.0 110 ± 19 
     
T259C 110 ± 6.6 103 ± 8.6 91 ± 13 91 ± 5.3 
     






All of the results presented above were obtained by using an EC5-10 concentration 
of glycine, determined individually for each oocyte.  Mascia et al. previously determined 
that application of propyl MTS resulted in a leftward shift in the glycine concentration 
response curve with no change in the maximum glycine response (Mascia et al., 2000).  
Consistent with this, we found that current induced by 1 mM glycine in the S267C, 
M263C and S270C mutants was not significantly changed by exposure to propyl MTS.  
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5.3 Discussion 
These results indicate that conformational changes occur in transmembrane 
segment two with channel gating.  Experiments conducted on three mutants; M263C, 
S267C, and S270C, provide evidence that accessibility to the region of the putative 
alcohol and anesthetic binding pocket changes with channel gating.  Under different 
conditions, MTS compounds covalently reacted at these positions to result in 
enhancement of glycine receptor function.   
 Experiments on S267C demonstrated that MTS reagents of longer lengths are able 
to react in the open state.  Importantly, there is a distinct length (octyl MTS) after which 
larger MTS compounds do not react with substituted cysteines in the closed state, but do 
react in the open state.  Methyl MTS, the smallest compound tested, did not cause a 
change in receptor function after application in either the closed or the open state, 
reinforcing the idea that a certain volume is needed to produce receptor enhancement.  
We noted the possibility that longer MTS compounds could “silently” react with the 
receptor without altering function, in which case we would not be able to detect the 
reaction.  By showing that propyl MTS enhancement was not blocked by a previous 
application of decyl MTS, we determined that decyl MTS is unable to reach the cysteine 
in the closed state.  Extrapolating, MTS compounds longer than decyl are not silently 
reacting with S267C and failing to enhance the receptor. 
The concentration response curve for propyl MTS on S267C in the open and 
closed states indicated that higher concentrations caused greater enhancement than the 50 
µM concentration initially used (Mascia et al., 2000).  The cause of inhibition with low 
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concentrations (or shorter applications) of propyl MTS and enhancement with higher 
concentrations (or longer applications) may represent differences in the number of 
glycine receptor subunits that have covalently reacted.  Reaction of MTS with a single 
subunit may result in inhibition, while reaction with multiple subunits results in 
enhancement.  Another possibility is that MTS may react when a cysteine is in two or 
more different conformational states. 
 The reaction rates of both propyl and hexyl MTS with S267C were faster in the 
presence of glycine than in the closed state, which provides further evidence of increased 
accessibility to S267 with channel opening.  These rates of reaction with propyl MTS 
were not altered with the addition of isoflurane.  It is interesting to note that propofol also 
did not protect the homologous TM2 positions from reaction with pCMBSֿ in a recent 
study in the GABA receptor α1 and β2 subunit, while protection was only seen for the β2 
subunit TM3 position (Bali and Akabas, 2004).  This can be interpreted in at least two 
ways:  1) the on and off rates of anesthetic binding at S267 are too quick to provide 
observable competition with a compound that covalently reacts at its target or 2) the drug 
binding site is elsewhere and isoflurane is not competing with MTS to bind at S267C.  
Present data do not allow us to definitively distinguish between these two possibilities. 
We found that increasing the MTS chain length increased the rate of reaction.  This may 
indicate that MTS compounds with longer chain lengths can reach the reactive cysteines 
more effectively through an amphipathic pathway or that the longer chain length MTS 
compounds are better stabilized near the reactive cysteine than shorter ones because of 
their lipophilic properties.  It should be noted that the potency of n-alcohols for 
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potentiation of glycine receptor function increases with chain length (Mascia et al., 
1996a; Wick et al., 1998). 
 When MTS reagents are coapplied with glycine, fractions of receptors exist in 
transitions between the closed, open and desensitized states.  By testing isoflurane 
potentiation of S267C following decyl MTS application in different receptor states, we 
found that both the desensitized and open states could be labeled, as indicated by the 
elimination of the isoflurane potentiation.  Additionally, a fraction of receptors were 
constitutively open following reaction with decyl MTS, suggesting that the open state had 
reacted and was stabilized. 
For the three substituted amino acids that reacted (M263C, S267C, and S270C), 
we observe distinctions in which compounds are able to access the site.  Some positions 
in the putative alcohol/anesthetic pocket accommodate longer MTS reagents in the 
presence of glycine, and others require agonist for reaction.  We attribute this change in 
accessibility to a change in the size and shape of the drug binding cavity.  An alternate 
hypothesis is that the access pathway to the cysteine has changed, allowing larger MTS 
reagents access to this region; however, such a mechanism does not appear to be 
sufficient to fully explain our data.  In particular, if glycine only increased the size of an 
access pathway to the drug binding region, we would expect M263C to react with decyl 
MTS in the open state in the same manner as S267C and S270C.  Since M263C reacts 
with propyl MTS, it must be in a water-filled cavity accessible to small MTS reagents.  
However, decyl MTS does not react with M263C, so access is not increased, and our data 
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is explained more accurately by a change in the volume/size of the drug binding cavity 
with channel gating. 
In contrast to S267C (Mascia et al., 2000), though binding by MTS reagents was 
possible on mutants M263C and S270C and caused an enhancement of receptor function, 
reaction with propyl MTS was unable to block further potentiation of the glycine receptor 
modulators isoflurane and octanol.  This may mean that the introduced MTS reagent is 
not the correct size or shape to mimic a drug molecule, and therefore prevent octanol and 
isoflurane action.  Another possibility is that these two positions are located in the 
alcohol and volatile anesthetic binding cavity, but they are not playing a direct role in 
binding isoflurane.   Still, both the M263C and S270C single mutations altered drug 
effects.  Both eliminated the effect of ethanol, and M263C reduced the potentiation by 
isoflurane.  Additionally, the potentiation by isoflurane was increased dramatically in the 
S270C mutant.  Though, propyl MTS was unable to block potentiation the effects of 
octanol and isoflurane, these two residues may play a role in stabilizing drug molecules 
in the binding cavity or allow the drug to be properly orientated to cause its effects. 
Mutations further toward the cytoplasm (G256C, T259C, V260C and T264C) 
were inaccessible to labeling by propyl and decyl MTS in the presence and absence of 
glycine.  Reaction with MTS is much faster when the cysteine is in a water-filled 
environment (Karlin and Akabas, 1998) and our results suggest that if the water-filled 
cavity does extend to this depth, it is not of sufficient size to admit MTS reagents. 
We compared our accessibility data for the glycine receptor (Lobo et al., 2004a) 
with the known reactivity data for TM2 in other ligand-gated ion channels (Akabas et al., 
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1994; Goren et al., 2004; Panicker et al., 2002; Reeves et al., 2001; Williams and Akabas, 
1999; Xu and Akabas, 1996; Zhang and Karlin, 1998) (Table 10).  Of all of the TM 
segments, TM2 has been studied in the most detail, in the most subunits and with the 
most sulfhydryl-reactive reagents.  In comparing the published SCAM data sets, there are 
many apparent differences and few commonalities.  For comparison, the amino acid 
prime number positions (Miller, 1989) and the glycine receptor position will be used and 
sequences were aligned using the consensus sequences for ligand-gated ion channels 
(Bertaccini and Trudell, 2002).  The 4’ position (G256) was inaccessible in all receptors 
tested.  The 7’ and 8’ positions were inaccessible in the glycine receptor, and most 
commonly inaccessible in the other receptors.  While the 11’ position (M263) was 
reactive in the glycine receptor, it was not accessible in any other receptor tested.  The 
15’ position (S267) was accessible in both the glycine receptor and the GABA receptor 
subunits tested (Goren et al., 2004; Williams and Akabas, 1999; Xu and Akabas, 1996).  
In glycine receptors reaction at S267C resulted in potentiation, while reaction in the 
GABA receptor subunits tested always resulted in inhibition.  The 15’ position was not 
accessible in the AChR alpha subunit but reacted in the beta subunit (Akabas et al., 1994; 
Zhang and Karlin, 1998), and there were mixed results for this position in the 5-HT3 
receptor (Panicker et al., 2002; Reeves et al., 2001).  The 18’ position (S270) reacted in 
the GABA receptor beta 1 subunit (Goren et al., 2004) and in the 5-HT3 receptor only 
with MTSEA (Panicker et al., 2002).  In the other receptors tested, or with other 
compounds, this position was not reactive.  The reactive residues differ from receptor to 
receptor and subunit to subunit making an overall amalgamation of these data sets 
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difficult in TM2.  These differences in accessibility may play a role in the way each of 
these channels is gated.  Since TM2 lines the channel pore, is responsible for gating, pore 
diameter and ion charge selectivity, variations in this segment of the protein may account 
for these functional differences. 
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Table 10 
TM 2 reactivity summary.  Our SCAM data for the TM2 glycine receptor mutants (Lobo 
et al., 2004a) is shown with other the known reactivity data for TM2 in other ligand-gated 
ion channels (Akabas et al., 1994; Goren et al., 2004; Panicker et al., 2002; Reeves et al., 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Our data that the water-filled cavity between the TM segments does not extend 
further towards the cytoplasm concurs with other evidence in the GABAA receptor β1 
subunit that the cytoplasmic end of TM2 is tightly packed against the rest of the protein, 
while the extracellular half of the helix is more loosely packed (Goren et al., 2004).  
Thus, the putative alcohol and anesthetic binding pocket of the glycine receptor extends 
three alpha helical turns into the transmembrane segment from the extracellular surface.  
MTS reagents can enter from the extracellular side, but being blocked from diffusing or 
reacting at positions below M263.  MTS reagents may enter via either a water-filled 
pathway or the lipid bilayer or a combination of the two, because both charged and 
neutral MTS compounds reacted.  This drug binding region was suggested to correspond 
to the space between the five TM2 alpha helices and the ring of 15 alpha helices 
surrounding them in the recent crystallographic structure of the acetylcholine receptor 
(Miyazawa et al., 2003).  Additionally, our data is consistent with the NMR structure of 
glycine receptor TM2 segments (Tang et al., 2002).  In comparing the NMR structure of 
wild type and S267Y (anesthetic resistant) TM2 segments of the glycine receptor, Tang et 
al. noted that the mutant caused only local conformation changes.  They predicted M263 
could border the amphipathic drug binding cavity (Tang et al., 2002), which is supported 
by our MTS labeling data. 
 Previous work estimates the anesthetic binding site in the anesthetic-sensitive 
protein firefly luciferase to be 250 ml/mol (or 415 Å3/molecule of protein) (Franks and 
Lieb, 1984).  Using a combination of mutagenesis and anesthetics of different sizes, 
Jenkins et al. estimated the volume of the anesthetic binding site in GABAA receptors to 
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be between 250 and 370 Å3 (Jenkins et al., 2001).  In our experiments, octyl MTS (269 
Å3; 204 Å3, after reaction with the cysteine) was the largest compound to produce glycine 
receptor enhancement in the S267C mutant in both states.  The largest compound tested, 
hexadecyl MTS, which affected the receptor only after application to the open state, has a 
molecular volume of 433 Å3 (368 Å3, after reaction).  This suggests that the volume of 
this cavity in the glycine receptor is similar to the anesthetic binding cavity in firefly 
luciferase and the GABAA receptor.
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6.0 Transmembrane Segment 3 
 
A portion of this chapter was published in an article in The Journal of Biological 
Chemistry in August 2004 and is reprinted with permission. ©2004 Journal of Biological 
Chemistry, American Society for Biochemistry and Molecular Biology, Inc., Bethesda, 
MD, 20814. 
 
Lobo IA, Mascia MP, Trudell JR, Harris RA. Channel gating of the glycine receptor 
changes accessibility to residues implicated in receptor potentiation by alcohols and 
anesthetics. J Biol Chem. 2004 Aug 6;279(32):33919-27. Epub 2004 May 28. 
 
 
6.1 Introduction to Transmembrane Segment 3 
An amino acid in TM3, A288, was identified a critical mediator of the 
potentiating effects of alcohols and/or volatile anesthetics on glycine receptors (Mihic et 
al., 1997).  Extensive mutagenesis at this position showed that the molecular volume of 
the amino acids substituted for A288 were negatively correlated with volatile anesthetic 
action (Yamakura et al., 1999).  This suggested that the volume of the putative volatile 
anesthetic and alcohol drug binding cavity was regulated by the size of the amino acid at 
the 288 position in TM3 (Yamakura et al., 1999).  A288 is hypothesized to line an 
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alcohol and anesthetic binding pocket at the center of the four transmembrane segments 
of each receptor subunit (Yamakura et al., 2001). 
These data make A288 an attractive target for mutagenesis and probing with MTS 
reagents using the substituted cysteine accessibility method.  By use of this method, 
residues accessible in the presence and/or absence of neurotransmitter to sulfhydryl-
specific reagents have been determined for TM3 in GABAA (Williams and Akabas, 1999) 
and the TM2-TM3 loop for GABAA receptors (Bera et al., 2002).  Lynch et al. (2001) 
demonstrated conformational changes occurring in the TM2-TM3 loop in the glycine 
receptor with gating (Lynch et al., 2001).  Additionally, Williams and Akabas have 
demonstrated that different GABAA receptor conformations are stabilized by the drugs 
diazepam and propofol using TM3 cysteine mutants (Williams and Akabas, 2000; 
Williams and Akabas, 2001; Williams and Akabas, 2002). 
As it is known that conformational changes occur in TM3 of the GABA receptor 
with channel gating as well as the TM2-TM3 loop, we tested whether changes in 
accessibility occurred at A288 in the glycine receptor.  In Chapter 4, we examined the 
ability of several differently sized, uncharged, MTS compounds to irreversibly occupy 
the S267C site of the glycine receptor under conditions where the channel was either 
closed (in the absence of glycine) or open (in the presence of glycine).  From these 
results, it followed logically to extend these studies to A288C.  Additionally, the rate of 
reaction of propyl MTS at A288C was determined and compared to the rate constants 
determined for S267C. 
 123
Previously, Mascia et al. demonstrated that covalent reaction of a drug analog 
(MTS) to S267C resulted in irreversible enhancement of receptor function and that the 
usual ability of octanol and isoflurane to enhance the receptor function was lost in the 
covalently bound receptors (Mascia et al., 2000).  This provided evidence that the action 
of alcohols and anesthetics at this position was due to binding in this region and not 
because S267 was an allosteric site.  In the present study, we examined this TM3 position 
for drug responses to ethanol, octanol and isoflurane.  Additionally, the ability of 
sulfhydryl-specific methanethiosulfonate (MTS) anesthetic analog to covalently react 






6.2.1 Concentration Response Curve Data 
The glycine EC50 values and the Hill slopes for this mutant were compared to the 
wild type receptor (Table 11).  The EC50 values for A288C increased significantly from 
that of the wild type receptor.   
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Table 11 
Glycine EC50 and Hill coefficients for the wild type (WT) receptor and the cysteine 
substitution mutants studied.  The glycine EC50 and Hill coefficients were experimentally 
calculated from concentration response curves and are expressed as a mean ± S.E. of 6 
oocytes for each receptor type. 
 
Glycine Receptor EC50 (µM) Hill Coefficient 
   
WT 280 ± 47 2.3 ± 0.56 
   
A288C 1800 ± 270 ** 2.0 ± 0.34 
 
*** p < 0.001; significantly different from WT receptor by the unpaired Student’s t-test.
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6.2.2 MTS Reactivity at A288C and WT Controls 
We chose propyl and decyl MTS to characterize A288C for accessibility to this 
position in TM3 in the presence and absence of glycine, and tested the same 
concentrations on the WT receptor.  Control propyl MTS applications (500 µM) on the 
WT receptor had no effect in the absence (100 ± 6 % of control, n = 4) or in the presence 
(110 ± 4 % of control, n = 4) of 1 mM glycine.  The control applications of decyl MTS 
(50 µM) also did not change the WT receptor function in the absence (86 ± 10 % of 
control, n = 4) or in the presence (83 ± 6 % of control, n = 4) of 1 mM glycine. 
In contrast, A288C showed state-dependence of accessibility.  For A288C, a 500 
µM propyl MTS application resulted in significant labeling in the presence of 1 mM 
glycine, but no change after application in the absence of glycine (Figure 21).  Decyl 
MTS (50 µM) also showed labeling of A288C in the presence, but not in the absence of 
glycine (Figure 21).  A lower concentration of propyl MTS (50 µM) had no significant 







Figure 21.  Labeling of GlyR α1 mutants A288C with propyl and decyl MTS.   
Propyl MTS (500 µM) and decyl MTS (50 µM) caused irreversible A288C receptor 
enhancement only when applied in the presence of 1 mM glycine (note that the scale of 
the Y axis is broken).  Data are expressed as a mean ± S.E. of 4 to 8 oocytes.  The paired 
Student’s t-test was used to determine significance of differences in the glycine EC5-10 
before and after treatment of MTS (* p < 0.05 and ** p < 0.01).
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6.2.3 Rates of Reaction of A288C with Propyl MTS 
 
 The rate of reaction of propyl MTS (500 µM) in the presence of glycine (1 mM) 
was measured for the A288C mutant.  Because this reaction was state dependent (i.e. 
required glycine), the rate could not be measured in the absence of glycine.  Ten second 
exposures of propyl MTS and glycine were applied until the reaction reached saturation 
point, or plateau, with no further increases in current with further applications.  The mean 
curve of the normalized currents indicates a complete reaction after 90 s of cumulative 





Figure 22.  Rate of reaction of propyl MTS with GlyR α1(A288C) in the presence of 
glycine.  Ten second exposures to 500 µM propyl MTS and 1 mM glycine were co-
applied to the A288C receptor until no further potentiation due to covalent reaction was 
measured.  The currents from each oocyte were normalized and plotted against the 
cumulative length of propyl MTS exposure.  The reaction was reached a plateau and was 
complete by 90 s. 
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6.2.4 Comparison of TM3 Rate with TM2 Rate 
The rate constants for the reaction of propyl MTS with A288C were calculated 
and compared to the TM2 (S267C) reaction rate data from Chapter 5.  While the TM2 
site is accessible in both conditions, the TM3 position is only accessible in the presence 
of glycine.  Additionally the reaction rate of S267C is significantly faster than that of 
A288C in the presence of glycine (Table 12). 
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Table 12 
Rates of reactions of propyl MTS with S267C and A288C in the absence of glycine and 
in the presence of 1 mM glycine.  The steady-state rates of reaction of propyl MTS is 
significantly faster with the TM2 site (S267C) than with TM3 site (A288C).  Rates are 
expressed as a mean ± S.E. of 6 to 12 oocytes. 
 
      
Mutant No Glycine (s-1M-1) 1 mM Glycine (s-1M-1) 
   
S267C 169 ± 29 1050 ± 190 
   
A288C no reaction 52 ± 8.3 ** 
      
 
** p < 0.01; significantly different from the corresponding S267C rate of reaction by the 
unpaired Student’s t-test.
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6.2.5 Responses of A288C to Alcohols and Volatile Anesthetics 
The responses of A288C to alcohols and anesthetics were determined and 
compared to the WT receptor.  Percent of control effects of ethanol (100 mM), octanol 
(115 µM), and isoflurane (0.8 mM) were tested on an EC5-10 of glycine.  The glycine EC5-
10 was determined for each oocyte.  The potentiation of ethanol and octanol was 
abolished in the A288C mutant.  The effect of isoflurane was significantly reduced in 
A288C compared to the WT glycine receptor (Table 13). 
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Table 13 
Percent of control responses of WT and A288C receptors to ethanol (100 mM), octanol 
(115 µM), isoflurane (0.8 mM) and chloroform (2.0 mM).  Percent of control responses 
were measured on the EC5-10 glycine responses (determined for each oocyte). 
 
 
Glycine Receptor Percent of Control 
    
 Ethanol Octanol Isoflurane 
    
WT 180 ± 11 270 ± 17 550 ± 50 
    
A288C 90 ±  13 *** 130 ± 23 *** 250 ± 30 *** 
    
 
 
Data are expressed as a percent of control of the mean ± S.E. of 4 to 16 oocytes.  Mutant 
responses were compared to the WT using the unpaired Student’s t-test (*** p < 0.001). 
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6.2.6 Response of A288C to Isoflurane Before and After Reaction with Propyl MTS 
A question that follows from these data is to ask whether the binding of MTS 
reagents at A288C blocks further potentiation of the glycine receptor response by 
alcohols and anesthetics.  This is good evidence that the MTS reagents are occupying the 
drug binding cavity and preventing a drug molecule from causing its effects on the 
receptor.  Previously, this experimental strategy was used previously to test the 
importance of the TM2 position S267 (Mascia et al., 2000). 
Because the A288C mutant was not sensitive to the effects of ethanol or octanol, 
but was potentiated by isoflurane (0.8 mM), the effect of isoflurane was tested before and 
after application of propyl MTS (500 µM).   Permanent occupation of the cysteine at 





Figure 23.  Reaction of propyl MTS with GlyR α1(A288C) prevents potentiation by 
isoflurane.  Isoflurane (0.8 mM) potentiation of the EC5-10 glycine was measured both 
before and after and application of 500 µM propyl MTS.  The initial potentiation by 
isoflurane was statistically different from the control.  Following reaction with propyl 
MTS, isoflurane did not cause any further potentiation of the glycine response.  Data are 
expressed as the mean ± S.E. of 9 and 6 oocytes for each bar, respectively.  The paired 
Student’s t-test was used to determine significance of the isoflurane potentiation of the 





The presented results were obtained by using an EC5-10 concentration of glycine, 
determined for each individual oocyte.  Previously, reaction of propyl MTS with S267C 
receptors was shown to result in a leftward shift in the glycine concentration response 
curve with no change in the maximum glycine response (Mascia et al., 2000).  Consistent 
with this, we found that current induced by 1 mM glycine in the A288C mutant was not 




In the glycine receptors, the TM3 mutation A288C shows state-dependence of 
water-accessibility.  This position is only reactive in the presence of glycine, indicating 
that channel gating increases accessibility of MTS to this position or increases the 
reactivity of the introduced cysteine.  Accessibility studies of the site homologous to 
A288 in TM3 in the GABAA receptor found that this position was also reactive in both 
the closed and open states with the neutral propyl and hexyl MTS (Jung et al., 
unpublished results, personal communication) and with the charged sulfhydryl-specific 
reagent pCMBS-  (Williams and Akabas, 1999).  The compound MTSEA did not react 
with this position of the GABAA receptor in either condition (Williams and Akabas, 





The reactivity data for the glycine receptors position A288  (Lobo et al., 2004a) is 
compared with accessibility studies in TM3 of the GABAA receptor with the neutral 
propyl and hexyl MTS (Jung et al., unpublished results, personal communication), 























































































































































































































































































































































































































In contrast to the GABAA receptor accessibility results, our results for the glycine 
receptor showed distinct reactivity only in the presence of agonist.  This may reflect a 
difference in the arrangement of the residues involved with alcohol/anesthetic between 
these two overall very similar inhibitory receptors.  One piece of experimental evidence 
that may reflect this difference between these receptors is the finding that 
nonhalogenated, alkane anesthetics potentiate glycine receptors, but have little to no 
effect on GABAA receptors (Hara et al., 2002; Raines et al., 2001). 
Previously, A288C was not observed to react with propyl MTS because of the 
lower concentration used (Mascia et al., 2000), suggesting that propyl MTS has less 
access to the position and a slower rate of reaction than what was measured for S267C.  
In comparing the reaction rate constant of propyl MTS in the presence of glycine at 
A288C with that of S267C, the reaction at the TM3 position is much slower.  Since 
agonist is necessary for MTS reaction with A288C, but is not required for S267C, this 
could account for a slower reaction rate at the A288 position.  The A288 position may 
have fewer water-accessible, open channel substates during which reaction can occur, 
making reaction a rarer event. 
This measured difference in rate constants is consistent with studies of reaction 
rate at homologous positions in the β2 subunit of GABAA receptor (Bali and Akabas, 
2004).  This study compared the rates of pCMBS- with the corresponding TM2 and TM3 
cysteine mutants.  The authors reasoned that this difference in rates may be caused by 
electrostatic interaction between the negatively charged pCMBS- and the positively 
charged arginine at the 19’ position in TM2 (one helical turn above the cysteine mutant in 
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TM2) (Bali and Akabas, 2004).  They hypothesized that this could cause an increased 
dwell time on the TM2 face, a higher local concentration of pCMBS- and therefore a 
higher reaction rate for the TM2 position (Bali and Akabas, 2004). 
In our studies, the neutral propyl MTS was used for chemical modification, 
making an explanation involving electrostatic interactions insufficient to explain our data.  
While the dwell time of MTS molecules at the TM2 face and S267 may be higher, 
another possible reason for this may be that the local environment surrounding A288 is 
not as favorable for reaction in comparison.  In the glycine receptor, on the TM2 helical 
face S267C is neighbored by S270 (above) and M263 (below).  Meanwhile, the residues 
neighboring A288 on the TM3 helical face are I285 (above) and L291 or L292 (below).  
While the serines on the TM2 face make this region polar, the alanine, isoleucine and 
leucine(s) on the TM3 face are in contrast very nonpolar.  Since the MTS molecule has a 
permanent dipole, dipole-dipole interactions may attract MTS to the TM2 face 
predominantly, resulting in a greater reaction. 
Upon permanent occupation of the cysteine at A288C by propyl MTS, the usual 
ability of isoflurane to potentiate the channel function was lost.  Results for the glycine 
receptor A288C mutant are consistent with the proposal that inhaled anesthetics and n-
alcohols are binding to a single location on the glycine receptor.  First, this substitution 
eliminates the usual receptor response to ethanol and octanol.  Second, the response of 
the receptor to isoflurane is abolished following irreversible binding by propyl MTS.  
Added to the previous mutagenesis studies (Mihic et al., 1997; Ueno et al., 1999; Wick et 
al., 1998; Yamakura et al., 1999), which indicated that A288 (and the equivalent position 
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in the GABAA receptor - A291) were critical for drug action on the receptor, these data 
are strong support that A288C is contributing to a binding site for alcohols and 
anesthetics. 
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7.0 Transmembrane Segment  4 
 
7.1 Introduction to Transmembrane Segment 4 
Among the four TM segments, TM4 is the least conserved and the most 
hydrophobic in terms of sequence.  In the recently published 4Å nicotinic acetylcholine 
receptor structure, the TM4 segment was imaged to be a helix though it was noted to be 
less precisely positioned than the others (Miyazawa et al., 2003).  TM4 and the other 
three transmembrane segments form a left handed bundle, and TM4 comes apart from 
this bundle toward the extracellular end (Miyazawa et al., 2003).  Data indicates that 
TM4 is mostly lipid-facing, with probable contact points with transmembrane segments 1 
and 3. 
Experimental data also supports an alpha helical secondary structure for TM4.  
Tryptophan substitution mutants in the TM4 segment of the Torpedo acetylcholine 
receptor α subunit showed that mutants with reduced activity all clustered along a single 
face of the helix away from the membrane lipids (Tamamizu et al., 2000).  The 
periodicity of labeling by the hydrophobic, photoactivable probes 2-[3H]-diazofluorene 
and [125I]TID of the α, β, γ, and δ subunits of the Torpedo acetylcholine receptor was also 
interpreted as being due to an alpha helical structure with a broad face of the helix in 
contact with lipids (Blanton and Cohen, 1992; Blanton and Cohen, 1994; Blanton et al., 
1998a). 
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The amino acids involved with alcohol and anesthetic action are predicted to face 
the center of the transmembrane domain of each glycine receptor subunit.  The putative 
binding cavity is at the center of the four transmembrane helices, with known amino 
acids from TM1, TM2 and TM3 lining the cavity.  This makes it possible that amino 
acids from TM4 also contribute to this drug binding cavity.  In the family of ligand-gated 
ion channels, there is evidence that TM4 residues may also play a role in alcohol and 
anesthetic binding and/or action.  Presently, it is unknown which specific amino acids are 
contributing to the drug binding pocket.  A study by Jenkins et al., twelve positions in the 
extracellular portion of TM4 were mutated to tryptophan in the α1 subunit of the GABAA 
receptor (Jenkins et al., 2002).  This study examined the effect of substituting a bulky 
amino acid in place of the wild type residues to change drug modulation by volatile 
anesthetics.  A number of positions were found to either increase or decrease the effects 
of isoflurane, halothane and chloroform (Jenkins et al., 2002), and these data will be 
compared to our studies of TM4 in the glycine receptor.  Additionally, the EC50 GABA 
values of the mutant receptors were plotted vs. the residue positions and were fitted to a 
sine curve with a period of 3.6 ± 0.1 residues (Jenkins et al., 2002).  This lends further 
support to the alpha helical arrangement of TM4. 
Experimentally, no one has determined accessibility for TM4 in any member of 
the ligand-gated ion channel family, so we were interested in testing whether TM4 had 
positions which were water-accessible.  This would give us more information about the 
structure of TM4 and indicate possible candidate positions critical for drug action.   
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Twelve single cysteine mutants in TM4 were made using site-directed 
mutagenesis and sequenced.  We chose the homologous positions to those in the GABAA 
receptor studied by Jenkins et al (2002).  They were first tested for their responses to 
glycine and then tested for their accessibility to the propyl methanethiosulfonate.  The 
ability of propyl MTS compound to irreversibly occupy these sites was tested under 
conditions where the channel is either closed or open using two-electrode voltage 
clamping in Xenopus oocytes.   
Mutants demonstrating accessibility were tested to see if they were responsive to 
alcohols (ethanol and octanol) and anesthetics (isoflurane and chloroform) both before 
and after reaction with propyl MTS.  This provided information on whether the position 
was affected by introduction of the cysteine itself, as well as indicating whether reaction 





7.2.1 Concentration Response Curve Data for the TM4 Mutants 
 First, the glycine concentration response curves for each of the twelve mutants 
TM4 mutants were determined.  The maximal glycine response was elicited at 1 mM 
glycine for all mutants except Y410C, which required 5 mM glycine for the maximal 
response.  For each mutant, the data was fitted for each oocyte with nonlinear regression 
curve fitting and the EC50 glycine and Hill coefficients were averaged.  These values, as 
well as the average maximal response to glycine, were compared to the WT receptors.  
The EC50 values were not significantly different from the WT by one-way ANOVA.   As 
a trend; however, all of the mutants had a lower sensitivity to glycine with W407C and 
Y410C having the lowest sensitivities and largest right shifts of their concentration 
response curves.  The Hill coefficients of the mutants also did not show significant 
changes from the WT receptors.   The maximal currents from the Y406C and Y410C 





Glycine EC50. Hill coefficients and maximal glycine currents for the wild type (WT) 
receptor and the cysteine substitution mutants studied in transmembrane segment 4.  The 
glycine EC50 and Hill coefficients were experimentally calculated from averaged 
concentration response curves of single oocytes.  Data are expressed as a mean ± S.E. of 
4 to 10 oocytes. 
 
 Receptor EC50 (µM) Hill Coefficient Max (µA) 
    
WT 104 ± 5.8 3.2 ± 0.8 16.9 ± 1.2 
I401C 198 ± 24 2.3 ± 0.2 11.9 ± 1.2 
F402C 147 ± 24 3.5 ± 1.2 13.4 ± 1.9 
N403C 283 ± 75 2.9 ± 0.2 15.1 ± 1.7 
M404C 112 ± 11 2.1 ± 0.2 16.6 ± 1.4 
F405C 190 ± 16 2.2 ± 0.2 21.3 ± 2.0 
Y406C 162 ± 22 2.9 ± 0.6 7.4 ± 1.4** 
W407C 731 ± 400 1.5 ± 0.2 13.8 ± 1.3 
I408C 386 ± 180 2.6 ± 0.7 14 ± 1.6 
I409C 197 ± 47 3.5 ± 0.5 13.6 ± 1.1 
Y410C 553 ± 110 2.3 ± 0.2 8.2 ± 1.3** 
K411C 290 ± 37 2.7 ± 0.4 13.2 ± 1.5 
I412C 206 ± 15 2.5 ± 0.5 13.9 ± 1.1 
 
** p < 0.01; significantly different from wild type receptors by one-way ANOVA with 
the Dunnett’s post test.
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7.2.2 Periodicity of TM4. 
By plotting the mean EC50 values of the TM4 cysteine mutants versus their 
position, periodicity of the data was apparent.   Using the cubic spline curve, the trend of 
the data points was shown.  Using this curve as a reference, a sine wave curve was fit to 
the data and the periodicity was calculated to be approximately 2.4 amino acids per turn 





Figure 24.  The mean EC50 values of the TM4 cysteine mutants were plotted versus 
their position.  The mean EC50 glycine value of the WT is marked as a solid, straight 
line.  All of the mutants had a greater EC50 value than the WT, with peaks at W407C and 
Y410C.  The cubic spline curve was shows the trend of the data points (dotted line).  A 
sine wave curve (solid line) was fit to the data with the cubic spline as a reference.  From 
the sine wave formula, the periodicity was calculated to be approximately 2.4 amino 
acids per turn of the helix. 
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7.2.3 MTS Reactivity Summary 
 The twelve cysteine mutants and WT glycine receptor were tested for irreversible 
changes in receptor function after application of propyl MTS.  The glycine EC5-10 was 
applied 10 minutes before and 10, 20 and 30 minutes after application of 500 µM propyl 
MTS.  The initial and the EC5-10 glycine responses at the 20 minutes time point was 
analyzed and compared.  Accessibility was tested in both the presence and absence of a 
maximal glycine concentration.  The maximal glycine concentration used for co-
application with propyl MTS was 1 mM for the WT all of the mutants except for Y410C, 
where 5 mM glycine was used due to its lower sensitivity. 
 The WT and the intracellular six amino mutated positions (I401C to W406C) 
were inaccessible to reaction with propyl MTS in both the presence and absence of 
glycine.  W407C reacted with propyl MTS, resulting in irreversible potentiation, under 
both conditions.  I408C was inaccessible under both conditions.  I409C only reacted in 
the presence of glycine, resulting in irreversible inhibition.  Y410C reacted with propyl 
MTS in both the presence and absence of glycine, resulting in irreversible potentiation.  
K411C reacted in both conditions, resulting in irreversible inhibition of the glycine 
current.  The final mutant, I412C, was inaccessible under both conditions.  
Representative tracings of the glycine responses before and after application of propyl 
MTS are shown for the WT, W407C, Y410C and K411C glycine receptors in Figure 25 




Figure 25.  Effect of propyl MTS on WT, W407C, Y410C and K411C glycine 
receptors.  The glycine current resulting from an EC5-10 of glycine was tested before and 
20 minutes after application of 500 µM propyl MTS.  Experiments were conducted in the 
absence and presence of glycine (1 mM).  Representative tracings are shown for the WT 
and three reactive mutants for closed state experiments. A) The glycine current of the WT 
was not altered following application of propyl MTS.  B) and C) Both W407C and 
Y410C were irreversibly enhanced after application of propyl MTS in the absence of 





Figure 26.  Accessibility of propyl MTS to GlyR α1 transmembrane 4 mutants. 
Propyl MTS (500 µM) was applied to receptors in the absence (Closed) and presence 
(Open) of a maximal concentration of glycine.  Four mutants reacted with propyl MTS to 
produce a change in the glycine EC5-10 response.  W407C and Y410C reacted in both the 
presence and absence of glycine and had a potentiated response to glycine.  I409C and 
K411C reacted with propyl MTS and showed inhibition of the initial glycine response.  
I409C only reacted with propyl MTS in the presence of glycine, while K411C reacted in 
both states.  Data are expressed as a mean ± S.E. of 5 to 11 oocytes.  All mutant 
responses were compared to the respective WT control by one-way ANOVA and the 
Dunnett’s post test (* p < 0.05, ** p < 0.01 and *** p < 0.001). 
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7.2.4 WT, Y410C and K411C Responses to Alcohols and Volatile Anesthetics 
The responses of two of these accessible mutants in TM4 to alcohols and 
anesthetic were determined and compared to the WT receptor.  Percent of control effects 
of ethanol (100 mM), octanol (115 µM), isoflurane (0.7 mM), and chloroform (2.0 mM) 
were tested on an EC5-10 concentration of glycine, which was determined for each oocyte.  
The Y410C mutant showed no potentiation to ethanol and significantly reduced 
potentiation to octanol.  K411C also showed no potentiation to ethanol, and additionally 
had a reduced isoflurane effect (Table 16). 
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Table 16 
Percent of control responses of WT, Y410C and K411C receptors to ethanol (100 mM), 
octanol (115 µM), isoflurane (0.7 mM) and chloroform (2.0 mM).  Percent of control 
responses were measured on the EC5-10 glycine responses (determined for each oocyte). 
 
Glycine Receptor Percent of Control 
     
 Ethanol Octanol Isoflurane Chloroform 
     
WT 180 ± 11 270 ± 17 820 ± 82 300 ± 35 
     
Y410C 62 ± 10 ** 140 ± 20 * 870 ± 110 510 ± 52 
     
K411C 85 ± 5 ** 200 ± 74 420 ± 49 ** 450 ± 66 
     
 
Data are expressed as a percent of control of the mean ± S.E. of 4 to 18 oocytes.  Mutant 
responses were compared to the WT using one-way ANOVA and Dunnett’s post-test (** 






7.2.5 Effects of Octanol, Isoflurane and Chloroform on Y410C and K411C Before 
and After Reaction with Propyl MTS 
Since both Y410C and K411C react with MTS and are water-accessible, we asked 
if the binding of MTS reagents at these positions could block further potentiation of the 
glycine receptor response by alcohols and anesthetics as shown previously (Mascia et al., 
2000).  If MTS reaction blocked further drug effects at these receptors, this would 
indicate that the MTS reagents were permanently occupying the drug binding cavity and 
thereby preventing another drug molecule from binding to and effecting the receptor. 
The effects of isoflurane (0.7 mM) and chloroform (2.0 mM) were tested on the 
EC5-10 glycine response of the Y410C.  Since K411C responded to octanol (115 µM), this 
alcohol was tested in addition to the two anesthetics on this receptor.  Next, propyl MTS 
was applied in the absence of glycine (90s) for reaction with the receptors, and the 
maximal glycine response and EC5-10 glycine concentration was re-determined.  Then the 
ability of propyl MTS (500 µM) to alter the responses of these two volatile anesthetics 
(and octanol for K411C) was determined.  Application of propyl MTS did not reduce or 




Figure 27. Effects of alcohols and anesthetics on Y410C and K411C receptors before 
and after application of propyl MTS.  The potentiation of the glycine EC5-10 by 
isoflurane (Iso; 0.7 mM) and chloroform (Chl; 2.0 mM) were measured before and after 
the application of 500 µM propyl MTS (in MBS).  Octanol (Oct; 115 µM) was tested 
only on K411C because it did not significantly potentiate Y410C receptors.  A) 
Application of propyl MTS to the Y410C receptor produced no change in the response of 
the receptor to isoflurane and chloroform.  B) Application of propyl MTS to the K411C 
receptor produced no change in the responses of the receptor to octanol, isoflurane and 
chloroform.  The Student’s paired t-test was used to determine differences in the mean 
drug potentiation from before and after the propyl MTS application (p>0.05 for all 
comparisons). 
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7.3 Discussion  
After mutagenesis of twelve positions in TM4 to cysteine and reaction with MTS 
reagents, water-accessible in the transmembrane 4 segment were determined.  Four 
positions in the extracellular portion of TM4 react with to produce an irreversible change 
in glycine receptor function.  This is the first accessibility study on TM4 in any ligand-
gated ion channel. 
The period of the EC50 values the cysteine mutants plotted vs. position for was 
approximately 2.4 residues.  This is less that the period of 3.6 ± 0.1 residues estimated by 
from the EC50 GABA values of TM4 tryptophan mutants (Jenkins et al., 2002).  One 
reason for this may be that the alpha helical arrangement of TM4 may be disturbed to a 
greater extent with cysteine mutations than with tryptophan mutations. 
The four reactive positions; W407, I409, Y410 and K411 were all located in the 
most extracellular portion of TM4.  Because TM4 is hypothesized to be surrounded by 
lipids, this is a somewhat surprising result.  The reactivity data indicates that these 
positions are in a water-filled environment.  Both W407C and Y410C were reactive in 
both the absence and presence of glycine.  Reaction at these positions resulted in an 
increased response to glycine.  I409C was reactive only in the presence of glycine and 
resulted in a decreased current.  The last reactive mutant, K411C, was reactive in both the 
absence and presence of glycine, and reaction resulted in an irreversible decrease in 
receptor current. 
 One aspect that complicates analysis of these data is the relative size of the native 
amino acids in TM4.  Overall, in the glycine receptor, the 12 amino acids targeted for 
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mutation were large.  Meanwhile, cysteine is a small amino acid in comparison.  With 
each introduced cysteine, the mutation itself may introduce a water-filled cavity where 
MTS may react.  These substitutions may enlarge existing water cavities or introduce 
new pockets of water.  This means it is possible that the native amino acid is not in a 
water-filled cavity in the wild type receptor.  Examples of this might include W407 and 
I409, two very hydrophobic amino acids, which are unlikely to be in a water-filled 
environment.  However, there is no alternative method to alleviate this problem, since 
cysteine is the only amino acid we can target with thiol-reactive reagents.  Until a high 
resolution crystal structure of TM4 is available for the glycine receptor, the precise 
orientation and surrounding environment of these residues will not be without question. 
 Both the W407C and Y410C  mutants have increased EC50 values and are less 
sensitive to glycine in comparison to the WT receptor.  Also, both of these mutants 
showed potentiation of the glycine response after reaction with propyl MTS.  One 
possible explanation of this is that the binding of propyl MTS at each of these introduced 
cysteines increases the volume occupied at these position to mimic the native amino 
acids.  Thus, reaction of propyl MTS could cause the mutant receptors to mimic the WT 
receptor to result in a leftward shift the glycine concentration response curve.  Another 
notable point is that these two amino acids should lie along the same helical face if TM4 
is an alpha helix.  This face of TM4 could be interacting with another TM region or part 
of the protein to regulate channel gating, and possibly drug action in the same manner. 
At present, two of the four accessible positions were tested to see if reaction with 
propyl MTS could block further potentiation by octanol and volatile anesthetics.  In 
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contrast to S267C (Mascia et al., 2000) and A288C (Chapter 6), propyl MTS reaction did 
not block further potentiation by drugs at Y410C and K411C.  Y410C was potentiated by 
isoflurane and chloroform both before and after reaction with propyl MTS.  The 
potentiation of K411C by octanol, isoflurane and chloroform was also unchanged by 
covalent reaction with propyl MTS.  One possible reason is that the introduced MTS 
reagent is not large enough or not the correct shape to mimic a drug molecule in the 
cavity, and therefore prevent drug action.  Reaction with a larger MTS reagent may be 
necessary to fill more of the drug binding pocket. 
 Alternative explanations may be that these two positions are not in the drug 
binding pocket, or that they are located in the alcohol and volatile anesthetic binding 
cavity but are not playing a direct role in binding these drugs.  These cysteine mutations 
themselves did affect drug action.  Y410C did not respond to ethanol or octanol, while 
K411C was not potentiated by ethanol and had a reduced isoflurane effect.  Although, 
propyl MTS did not prevent alcohol/anesthetic potentiation, it is not yet possible to 
exclude these two residues as candidates for participation in a drug binding cavity. 
To this date, there have been no other SCAM studies on TM4 on any other ligand-gated 
ion channels.  For this reason, these data were compared to published data on tryptophan 
mutants in TM4 of the Torpedo californica nicotinic acetylcholine receptor α subunit 
(Tamamizu et al., 2000) and the α1 subunit of the GABAA receptor (Jenkins et al., 2002) 
(Table17).  These sequences were aligned using the using the consensus sequences of the 
ligand-gated ion channels (Bertaccini and Trudell, 2002).  The amino acids postulated to 
be lipid-facing in the acetylcholine receptor were not water-accessible in the glycine 
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receptor with the exception of I409C.  I409C showed a decrease in receptor function after 
reaction in the presence of glycine, indicating a possible shift from a lipid-facing to a 
water-facing position.  Another possibility is that the mutation from isoleucine to cysteine 
created a new water pocket in a previously unexposed position.  Also, the glycine 
receptor mutant W407C did not cause any significant change in receptor, while mutation 
at the aligned position in the acetylcholine receptor (V423W) resulted in decreased 
expression. Comparison of our glycine receptor results with those of the GABAA receptor 
showed some overlap, and also differences.  Jenkins et al. tested whether tryptophan 
mutations altered receptor sensitivity to three volatile anesthetics: isoflurane, halothane 
and chloroform (Jenkins et al., 2002).  While there was no reactivity with MTS observed 
for positions I401, F402, Y406 and I412, mutation to tryptophan could alter anesthetic 
effects.  The glycine receptor mutant W407C was reactive, but could not be compared to 
the GABAA receptor results, where the position was already a tryptophan.  Meanwhile, 
overlap between these data sets occurred with the three other water-accessible positions.  
Positions I409, Y410 and K411 were all water accessible in the glycine receptor, and 




Since no other SCAM studies have been completed on TM4, the glycine receptor TM4 
reactivity data is compared with published data on tryptophan mutants in the TM4 
segments of the Torpedo californica nicotinic acetylcholine receptor α subunit 



























































































































































































































































































































































































































Although it is not certain at this point if the four water-accessible TM4 mutations 
are contributing to an alcohol and anesthetic binding cavity, these positions have been 
defined as candidates worthy of further study.
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8.0 Conclusions and Discussion 
 
Portions of this chapter were published in articles in Journal of Neurochemistry and in 
The Journal of Biological Chemistry in August 2004.  This material is reprinted with 
permission.  © Journal of Neurochemistry, International Society for Neurochemistry and 
Blackwell Publishing  and ©2004 Journal of Biological Chemistry, American Society for 
Biochemistry and Molecular Biology, Inc., Bethesda, MD, 20814. 
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Lobo IA, Mascia MP, Trudell JR, Harris RA. Channel gating of the glycine receptor 
changes accessibility to residues implicated in receptor potentiation by alcohols and 
anesthetics. J Biol Chem. 2004 Aug 6;279(32):33919-27. Epub 2004 May 28. 
 
 
 This thesis work has further defined the putative alcohol and volatile anesthetic 
binding site in the glycine receptor.  The use of mutagenesis, crosslinking, and probing 
with sulfhydryl-specific reagents has identified new characteristics of this cavity.  The 
interface between TM2 and TM3 has been located and better defined by crosslinking two 
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amino acids known to be critical for volatile anesthetic and alcohol action.  Water-
accessible positions were identified in all four transmembrane segments by reaction with 
sulfhydryl-specific probes.  Additionally, conformational changes, as demonstrated by 
changes in reactivity to MTS reagents, were observed for positions in all four 
transmembrane segments with channel gating. 
 
Positioning Transmembrane Segments 
 The results presented in Chapter 3 suggest that an intrasubunit disulfide bond 
forms between S267C and A288C in GlyR α1(S267C/A288C) receptors.  These two 
amino acids have been shown to be critical for alcohol and volatile anesthetic action and 
hypothesized to line a binding pocket for alcohols and volatile anesthetics between the 
four transmembrane segments in the GlyR subunit  (Jenkins et al., 2001; Mascia et al., 
2000; Mihic et al., 1997; Wick et al., 1998; Yamakura et al., 2001).  By crosslinking 
these two residues, the close positioning of these two amino acids was determined. 
Our results indicate that S267 and A288 face a common pocket within each 
subunit.  Also, crosslinking allowed the distance between the alpha carbons of S267 and 
A288 to be estimated at approximately 7 Å.  Since the vertical position of TM2 with 
respect to TM3 was previously undetermined, disulfide bonding between these two 
introduced cysteines provides insight regarding the location and role of the TM2-TM3 
interface. 
With respect to these two positions and the newly identified water-accessible 
positions in TM2, TM4 and TM1, it would be useful to create double mutants to see if 
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crosslinking occurs between other pairs of transmembrane segments.  Many of the 
cysteine mutants tested resulted in a reduction or a loss of drug potentiation.  Of these 
positions, it is not yet certain whether these amino acids also line the drug binding cavity.   
If they do participate directly in drug binding, then knowledge of the orientation of these 
amino acid side chains would be very useful.  Not only would this provide information on 
the alcohol and anesthetic binding cavity, crosslinking (via disulfide reaction, or 
crosslinking reagents) would provide structural data to position transmembrane segments 
more definitively. 
 
How Does Channel Gating Alter Glycine Receptor Conformation? 
The gating mechanism of ligand-gated ion channels is not entirely understood.  
The binding of small neurotransmitters at locations in the extracellular domain, far from 
the pore, causes conformational changes in the transmembrane region, allowing for ion 
conductance.  The gating mechanism of ion channels may involve rearrangement of a 
sub-region within the pore itself, the entire pore, or may cause the channel structure to be 
even more substantially altered.  Because the energy of agonist binding is small, it would 
be difficult to explain any major structural movement in the protein during gating.  Also, 
it would be unfavorable for the rearrangements to be extensive since the channel must 
soon close.  Better supported experimentally is a cascade model involving local changes 
that rearrange low energy interactions (Kash et al., 2004).  From ligand binding, the 
signal is transduced through the N-terminal extracellular domain, through the TM2-TM3 
linker (Kash et al., 2003) and causes a twisting of the barrel of TM2 helices to open the 
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channel (Unwin, 1995; Unwin, 1998).  The opening of the channel has been modeled by 
equivalent 15 degree rotations of all five TM2 helices (Unwin, 2003). 
When the transduction signal reaches the transmembrane domain, TM2 moves.  It 
would make sense that TM3 may move as well, causing the state-dependent change in 
accessibility observed at A288.  While it is obvious that the lining of the channel changes 
conformation with channel gating and that TM3 may move because of transduction 
through the linker, it is perhaps unexpected that TM1 and TM4 also show differences in 
accessibility with channel gating.  Previous studies have identified differences in 
accessibility in receptor subunits when neurotransmitter was present or absent.  From 
these data, amino acids in all four transmembrane segments of the glycine receptor have 
alterations in accessibility with channel gating.  Meanwhile, other positions were always 
in water-accessible and reactive positions, or were inaccessible under all conditions 
tested. 
 
Conformational Changes in the Alcohol and Anesthetic Binding Cavity 
Our results on the TM2 mutant S267C indicated that conformational changes 
occurring during channel gating increased the size of the binding cavity.  While short 
chain MTS reagents reacted in the closed state of the receptor, both short and longer 
chain MTS compounds reacted in the presence of glycine.  Additionally, our data showed 
increased accessibility or reactivity in the open state of the channel, indicating changes in 
the local environment of area of the protein. 
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 For both I229C and A288C, there is a distinct conformational change occurring 
with channel gating that allows MTS to react only in the presence of glycine.  The state-
dependence of reaction indicates that there are specific conformational changes with 
channel gating occurring even in TM1 and TM3 of the GlyR, along with the necessary 
changes in TM2, completely altering the accessibility to these two positions.  Previously, 
A288C was not observed to react with propyl MTS because of the lower concentration 
used (Mascia et al., 2000).  A slower reaction rate with propyl MTS was measured for 
A288C than the rate of reaction at S267C.  This is most likely because propyl MTS has 
less access to the A288 position or the local environment is not as conducive to reaction 
as that surrounding S267.  Another TM2 position, M263C, reacted with propyl MTS, but 
not with decyl MTS, demonstrating that compounds of this length are too large to access 
this cysteine.  For S270C, propyl MTS reacted in both states, but the larger decyl MTS 
reacted only in the presence of glycine, indicating that the water-filled space around this 
position increased in the open state. 
 Though the positioning of the amino acids in TM4 are not yet definitive, four 
cysteine mutants were accessible to propyl MTS: W407C, I409C, Y410C and K411C.  
I409C was only accessible in the presence of glycine, while the other three amino acids 
were accessible in both the closed and open state.  Because these four amino acids, 
located in the extracellular portion of TM4 where they could face the other 
transmembrane segments and are water-accessible, these positions are candidates for 
participating in the alcohol and anesthetic drug binding cavity.  The same holds true for 
the TM1 position I229.  Further experiments to test if longer chain MTS reagents can 
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block potentiation by drugs and crosslinking experiments would lend more evidence to 
determine whether these positions are playing a role in drug binding or not. 
 
Proposed Mechanism for Drug Action 
Our results lead us to a potential mechanism for alcohol and anesthetic action on 
the glycine receptor and other related ligand-gated ion channels.  Because we have 
evidence that the site of action of alcohols and volatile anesthetics experiences 
conformational changes during channel gating, this in turn suggests that drugs occupying 






Figure 28.  Schematic view showing a slice view through a glycine receptor 
transmembrane region. Only two pairs of transmembrane 2 and 3 segments are shown 
for a single glycine receptor.  When glycine is not present, the channel is closed, and no 
chloride ions can flow through the pore lined by the TM2 segments.  Upon the addition 
of glycine, the channel gate can open allowing for conductance through the pore.  We 
hypothesize that alcohols or volatile anesthetics (A) bind in a water-filled cavity formed 
in part by residues from TM2 and TM3, which results in stabilization of the channel’s 
open state. 
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Molecular Modeling of the Alcohol and Volatile Anesthetic Binding Cavity 
The structural model of GlyR α1 derived by Trudell and Bertaccini (in press) 
shows S267 and A288 in proximity (Figure 29).  The proximity of these two residues and 
their orientation toward the center of the subunit is consistent with studies that showed 
additivity of the side chain volumes of these residues in changing the cutoff of long chain 
alcohols (Wick et al., 1998) and potentiation by anesthetics (Jenkins et al., 2001).  In 
addition, the proximity of these residues is consistent with the ability of a double 
mutation (S267C/A288C) to form disulfide bonds (Lobo et al., 2004b).  Although it is 
possible for side chains of distant residues to form disulfide bonds during thermal-motion 
induced excursions from their mean positions, the highest reaction rate is expected when 
the Cα to Cα distance is approximately 6 Å (Lobo et al., 2004b). 
Experiments conducted on five mutants; I229C, M263C, S267C, S270C and 
A288C, provide evidence that accessibility to the region of the putative alcohol and 
anesthetic binding cavity changes with channel gating.  Under different conditions, MTS 
compounds covalently reacted at these positions to result in enhancement of glycine 
receptor function.  These data are shown in a homology model of GlyR α1 (Trudell and 
Bertaccini, 2004; Yamakura et al., 2001), where the reactive positions are rendered with 
space-filling surfaces, while the non-reactive positions tested are shown as ball and stick 
surfaces (Figure 29A and 29B).  The disulfide bond to hexyl sulfide (formed after the 
reaction with hexyl MTS) was modeled for the S267C receptor.  Positioning was based 
by forming the disulfide bond and then re-optimizing the GlyR model with harmonic 
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restraints on all the backbone atoms of the subunit to illustrate a likely orientation and 




Figure 29.  Molecular model of the transmembrane domain of one subunit of GlyR 
α1 that was built by threading the primary sequence of GlyR α1 onto a template of 
a four-helical bundle.  A) The homology model viewed from the side in the plane of the 
membrane shows a putative alcohol and anesthetic binding pocket, a cavity in the center 
of the receptor subunit.  Residues that did react with MTS reagents are rendered with 
space-filling surfaces (I229, M263, S267, S270, and A288), and those that did not are 
rendered with ball and stick surfaces (G256, T259, V260, T264).  The peptide backbone 
is shown as a red ribbon.  B) The same model as A) viewed from the extracellular surface 
and looking into the center of the four-helical bundle.  C) The model viewed from the 
side in the plane of the membrane with a disulfide bond to hexyl sulfide (formed after the 
reaction with hexyl MTS) from the sulfur atom of S267C in the mutated receptor.  The 
four alpha helices are rendered as transparent yellow cylinders, the random coils as green 
ribbons.   D) The same model as C viewed from the extracellular surface and looking into 
the center of the four-helical bundle. 
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Discussion of SCAM data 
 
As in other studies using sulfhydryl reagents as probes, our experimental design 
leaves the native cysteines of the receptor intact (Akabas et al., 1992; Karlin and Akabas, 
1998; Mascia et al., 2000).  Observing no change in the WT response following any of 
the MTS reagents used, we assume that mutant receptors have a structure and properties 
similar to the WT receptors and that enhancement is due to specific reaction of MTS at 
the introduced cysteines.   
As with all mutagenesis studies, it is important to keep in mind the limitations that 
are inherent to trying to examine a WT proteins’s function in an altered protein.  The 
single amino acid substitutions are presumed to change only local conformations rather 
than cause substantial alterations in receptor structure.  We must keep in mind that 
definitive placement of an alcohol and volatile anesthetic binding site will only be 
accomplished when a glycine receptor is crystallized with a bound alcohol or anesthetic 
molecule. 
 
What is an Alcohol and Volatile Anesthetic Binding Site? 
We are left with the question of what constitutes an alcohol and volatile anesthetic 
binding site.  Since the putative alcohol and volatile anesthetic binding cavity is 
composed of amino acids contributed from different receptor segments, rather than being 
composed of a single stretch of amino acids in more easily identifiable motif, it is a 
greater challenge to identify all of the positions contributing to these cavities.  Also, it 
will be a challenge to compare the binding cavity in the glycine receptor to those in other 
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proteins known to be affected by alcohols and anesthetics.  At present, it is not possible to 
search through high resolution, tertiary protein structures to identify drug binding sites in 
proteins known to respond to drugs, or to find candidate proteins which may bind 
alcohols and anesthetics. 
We are still learning about what constitutes an alcohol and volatile anesthetic 
binding site in a few known proteins.  From experiments using firefly luciferase, a 
soluble protein which is inhibited by anesthetics, it was suggested that anesthetics bind to 
an amphipathic cavity of defined dimensions (Franks and Lieb, 1985).  Also, 
crystallographic data of the anesthetic bromoform bound to the firefly luciferase enzyme 
showed that there were minimal changes in overall protein structure as a result of 
anesthetic binding (Franks et al., 1998).   
A recent study on the odorant binding protein LUSH from Drosophila 
melanogaster showed that short-chain alcohols bound to a single site (Kruse et al., 2003).  
This cavity is normally hydrated.  When ethanol or butanol occupied the binding site 
between two alpha helical segments, the protein’s conformation was stabilized 
profoundly.  Water is described as an ideal ligand for displacement from drug binding 
cavities, serving to increase the binding energy of drug molecules (Trudell and Harris, 
2004).  Thus, as in LUSH, the binding of small drug molecules, like alcohols and volatile 
anesthetics, have the ability to stabilize protein conformations. 
The theme of alcohols and anesthetics binding between alpha helices, or within 
pockets formed by turn/loop regions and their adjacent alpha helices was suggested in an 
analysis of protein segments characterized for alcohol/anesthetic binding by high-
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resolution 3-D structures and mutagenesis (Dwyer and Bradley, 2000).  It was concluded 
that alcohols mainly act as hydrogen bond donors with other hydrophobic interactions 
stabilizing binding (Dwyer and Bradley, 2000).  In LUSH, a motif of amino acids 
containing hydroxyls formed the alcohol binding site (Kruse et al., 2003).   Kruse et al. 
speculated that this motif of serines and threonines could be conserved in other proteins 
(Kruse et al., 2003).  The role of one of these serines in the glycine receptor could be 
served by S267. 
Our data for the glycine receptor suggest that alcohols and volatile anesthetics 
bind to a water-filled protein cavity that is formed by at least two alpha helical segments.  
While we are not yet at a stage to compare the final structure alcohol and anesthetic 
binding site of the glycine receptor with those in other proteins, the use mutagenesis, 
biochemistry and molecular modeling have advanced the available structural information.  
From the known data, the glycine receptor’s drug binding pocket is amphipathic, with 
hydrophilic regions contributed by S267 in TM2 (and possibly TM4) function as a 
hydrogen bond acceptor.  Meanwhile hydrophobic amino acids in TM3 (A288), along 
with TM1 and TM4, could serve to stabilize drug binding for the hydrophobic end of the 
drug molecule.  In the glycine receptor, occupation of this site by alcohols and volatile 
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